JP2013501064A - リゾホスファチジン酸受容体アンタゴニストとしての化合物 - Google Patents

Info

Publication number

JP2013501064A

JP2013501064A JP2012523709A JP2012523709A JP2013501064A JP 2013501064 A JP2013501064 A JP 2013501064A JP 2012523709 A JP2012523709 A JP 2012523709A JP 2012523709 A JP2012523709 A JP 2012523709A JP 2013501064 A JP2013501064 A JP 2013501064A

Authority

JP

Japan

Prior art keywords

phenyl

compound

methyl

isoxazol

ethoxycarbonylamino

Prior art date

2009-08-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 455
• 229940123977 Lysophosphatidic acid receptor antagonist Drugs 0.000 title description 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 108
• 201000010099 disease Diseases 0.000 claims abstract description 82
• 238000000034 method Methods 0.000 claims abstract description 67
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 49
• 230000001404 mediated effect Effects 0.000 claims abstract description 42
• 230000001419 dependent effect Effects 0.000 claims abstract description 25
• -1 cyclopropyl-1, 1-diyl Chemical group 0.000 claims description 191
• 241000124008 Mammalia Species 0.000 claims description 75
• 229910052799 carbon Inorganic materials 0.000 claims description 66
• 206010016654 Fibrosis Diseases 0.000 claims description 63
• 230000004761 fibrosis Effects 0.000 claims description 60
• 229910052739 hydrogen Inorganic materials 0.000 claims description 56
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 55
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 48
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 45
• 125000000217 alkyl group Chemical group 0.000 claims description 45
• 150000003839 salts Chemical class 0.000 claims description 44
• 125000003118 aryl group Chemical group 0.000 claims description 41
• 238000011282 treatment Methods 0.000 claims description 40
• 229910052731 fluorine Inorganic materials 0.000 claims description 38
• 229910052801 chlorine Inorganic materials 0.000 claims description 37
• 206010028980 Neoplasm Diseases 0.000 claims description 34
• 229910052736 halogen Inorganic materials 0.000 claims description 34
• 125000001072 heteroaryl group Chemical group 0.000 claims description 34
• 125000002947 alkylene group Chemical group 0.000 claims description 33
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 33
• 208000006673 asthma Diseases 0.000 claims description 32
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 30
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 29
• 229940002612 prodrug Drugs 0.000 claims description 29
• 239000000651 prodrug Substances 0.000 claims description 29
• 201000011510 cancer Diseases 0.000 claims description 28
• 150000002367 halogens Chemical class 0.000 claims description 27
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 26
• 210000001519 tissue Anatomy 0.000 claims description 26
• 208000019425 cirrhosis of liver Diseases 0.000 claims description 25
• 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 25
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 24
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 24
• 210000000056 organ Anatomy 0.000 claims description 24
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 23
• 230000015572 biosynthetic process Effects 0.000 claims description 21
• 239000003826 tablet Substances 0.000 claims description 21
• 125000004432 carbon atom Chemical group C* 0.000 claims description 20
• 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 19
• 125000002993 cycloalkylene group Chemical group 0.000 claims description 19
• 208000005069 pulmonary fibrosis Diseases 0.000 claims description 19
• 125000000732 arylene group Chemical group 0.000 claims description 18
• 239000002775 capsule Substances 0.000 claims description 18
• 239000012453 solvate Substances 0.000 claims description 17
• 239000002904 solvent Substances 0.000 claims description 17
• 229910052794 bromium Inorganic materials 0.000 claims description 16
• 208000024891 symptom Diseases 0.000 claims description 16
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 15
• 239000002253 acid Substances 0.000 claims description 15
• 125000004474 heteroalkylene group Chemical group 0.000 claims description 15
• 125000000623 heterocyclic group Chemical group 0.000 claims description 15
• 208000027866 inflammatory disease Diseases 0.000 claims description 15
• 239000003112 inhibitor Substances 0.000 claims description 15
• 229910052740 iodine Inorganic materials 0.000 claims description 15
• 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 13
• 239000006185 dispersion Substances 0.000 claims description 13
• 125000005549 heteroarylene group Chemical group 0.000 claims description 13
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 13
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 12
• 230000002265 prevention Effects 0.000 claims description 12
• 201000002793 renal fibrosis Diseases 0.000 claims description 12
• 208000023504 respiratory system disease Diseases 0.000 claims description 12
• 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 11
• 206010039710 Scleroderma Diseases 0.000 claims description 11
• 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 11
• 125000005843 halogen group Chemical group 0.000 claims description 11
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 11
• 125000004434 sulfur atom Chemical group 0.000 claims description 11
• 208000002193 Pain Diseases 0.000 claims description 10
• 231100000241 scar Toxicity 0.000 claims description 10
• 239000000725 suspension Substances 0.000 claims description 10
• 238000003786 synthesis reaction Methods 0.000 claims description 10
• 206010027476 Metastases Diseases 0.000 claims description 9
• 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 9
• 230000009401 metastasis Effects 0.000 claims description 9
• 208000004296 neuralgia Diseases 0.000 claims description 9
• 239000000243 solution Substances 0.000 claims description 8
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
• 206010009944 Colon cancer Diseases 0.000 claims description 7
• 206010033128 Ovarian cancer Diseases 0.000 claims description 7
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
• 239000006187 pill Substances 0.000 claims description 7
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
• 210000001035 gastrointestinal tract Anatomy 0.000 claims description 6
• 238000001990 intravenous administration Methods 0.000 claims description 6
• 208000017169 kidney disease Diseases 0.000 claims description 6
• 208000019423 liver disease Diseases 0.000 claims description 6
• 208000017520 skin disease Diseases 0.000 claims description 6
• 210000001635 urinary tract Anatomy 0.000 claims description 6
• ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 5
• 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 5
• 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 5
• 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 5
• 102000015439 Phospholipases Human genes 0.000 claims description 5
• 108010064785 Phospholipases Proteins 0.000 claims description 5
• 206010060862 Prostate cancer Diseases 0.000 claims description 5
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 5
• 239000013543 active substance Substances 0.000 claims description 5
• 239000003172 expectorant agent Substances 0.000 claims description 5
• 239000000499 gel Substances 0.000 claims description 5
• 239000005414 inactive ingredient Substances 0.000 claims description 5
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 5
• 238000007920 subcutaneous administration Methods 0.000 claims description 5
• 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims description 4
• 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims description 4
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 4
• 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 4
• 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
• 208000001640 Fibromyalgia Diseases 0.000 claims description 4
• 206010072877 Intestinal fibrosis Diseases 0.000 claims description 4
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
• 150000007513 acids Chemical class 0.000 claims description 4
• 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
• 108010022198 alkylglycerophosphoethanolamine phosphodiesterase Proteins 0.000 claims description 4
• 239000002246 antineoplastic agent Substances 0.000 claims description 4
• 206010008118 cerebral infarction Diseases 0.000 claims description 4
• 208000029742 colonic neoplasm Diseases 0.000 claims description 4
• 239000003246 corticosteroid Substances 0.000 claims description 4
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 4
• 239000003018 immunosuppressive agent Substances 0.000 claims description 4
• 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 4
• 201000001441 melanoma Diseases 0.000 claims description 4
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 4
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
• 125000006413 ring segment Chemical group 0.000 claims description 4
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
• 206010006187 Breast cancer Diseases 0.000 claims description 3
• 208000026310 Breast neoplasm Diseases 0.000 claims description 3
• 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 3
• 229940122444 Chemokine receptor antagonist Drugs 0.000 claims description 3
• 208000029147 Collagen-vascular disease Diseases 0.000 claims description 3
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
• 206010023421 Kidney fibrosis Diseases 0.000 claims description 3
• 208000016222 Pancreatic disease Diseases 0.000 claims description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
• 108010016133 acylglycerol kinase Proteins 0.000 claims description 3
• 230000000954 anitussive effect Effects 0.000 claims description 3
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
• 239000000739 antihistaminic agent Substances 0.000 claims description 3
• 229940124584 antitussives Drugs 0.000 claims description 3
• 208000021328 arterial occlusion Diseases 0.000 claims description 3
• 229940124748 beta 2 agonist Drugs 0.000 claims description 3
• 229940124630 bronchodilator Drugs 0.000 claims description 3
• 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
• 239000002559 chemokine receptor antagonist Substances 0.000 claims description 3
• 229960001334 corticosteroids Drugs 0.000 claims description 3
• 239000000850 decongestant Substances 0.000 claims description 3
• 206010013990 dysuria Diseases 0.000 claims description 3
• 239000000839 emulsion Substances 0.000 claims description 3
• 230000003419 expectorant effect Effects 0.000 claims description 3
• 239000003889 eye drop Substances 0.000 claims description 3
• 229940043355 kinase inhibitor Drugs 0.000 claims description 3
• 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 3
• 150000002617 leukotrienes Chemical class 0.000 claims description 3
• 239000006210 lotion Substances 0.000 claims description 3
• 208000002780 macular degeneration Diseases 0.000 claims description 3
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
• 230000027939 micturition Effects 0.000 claims description 3
• 239000007922 nasal spray Substances 0.000 claims description 3
• 239000002674 ointment Substances 0.000 claims description 3
• 201000002528 pancreatic cancer Diseases 0.000 claims description 3
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
• 239000003358 phospholipase A2 inhibitor Substances 0.000 claims description 3
• 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 3
• 208000031104 Arterial Occlusive disease Diseases 0.000 claims description 2
• 206010058019 Cancer Pain Diseases 0.000 claims description 2
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
• 239000000084 colloidal system Substances 0.000 claims description 2
• 239000003221 ear drop Substances 0.000 claims description 2
• 201000010536 head and neck cancer Diseases 0.000 claims description 2
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
• 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
• 229940097496 nasal spray Drugs 0.000 claims description 2
• 239000000829 suppository Substances 0.000 claims description 2
• 238000011200 topical administration Methods 0.000 claims description 2
• VTOLOLFIARHIQS-MRXNPFEDSA-N 2-[4-[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(CC(O)=O)C=C1 VTOLOLFIARHIQS-MRXNPFEDSA-N 0.000 claims 4
• OIPIOGBLKYRDIU-ZYMOGRSISA-N 2-[4-[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]propanoic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(C(C)C(O)=O)C=C1 OIPIOGBLKYRDIU-ZYMOGRSISA-N 0.000 claims 4
• KPAUUYLOOZUGRX-MRXNPFEDSA-N [(1r)-1-(2-fluorophenyl)ethyl] n-[5-methyl-3-[4-[4-(2h-tetrazol-5-ylmethyl)phenyl]phenyl]-1,2-oxazol-4-yl]carbamate Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1CC=1N=NNN=1 KPAUUYLOOZUGRX-MRXNPFEDSA-N 0.000 claims 3
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
• QQYKNIYGHWQHFS-UHFFFAOYSA-N 1-[4-[4-[4-(1-cyclohexylethoxycarbonylamino)-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound C1CCCCC1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 QQYKNIYGHWQHFS-UHFFFAOYSA-N 0.000 claims 2
• XOOGIWLVINMKGN-UHFFFAOYSA-N 1-[4-[4-[4-(1-cyclopropylethoxycarbonylamino)-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound C1CC1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 XOOGIWLVINMKGN-UHFFFAOYSA-N 0.000 claims 2
• VXBNRHLXKMCWDW-UHFFFAOYSA-N 1-[4-[4-[4-(cyclobutyloxycarbonylamino)-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound CC=1ON=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C2(CC2)C(O)=O)C=1NC(=O)OC1CCC1 VXBNRHLXKMCWDW-UHFFFAOYSA-N 0.000 claims 2
• DAJGTVDHWZJARM-UHFFFAOYSA-N 1-[4-[4-[4-(cyclopropylmethoxycarbonylamino)-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound CC=1ON=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C2(CC2)C(O)=O)C=1NC(=O)OCC1CC1 DAJGTVDHWZJARM-UHFFFAOYSA-N 0.000 claims 2
• FYSJYHFUXLPBKT-UHFFFAOYSA-N 1-[4-[4-[4-(ethoxycarbonylamino)-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound CCOC(=O)NC1=C(C)ON=C1C1=CC=C(C=2C=CC(=CC=2)C2(CC2)C(O)=O)C=C1 FYSJYHFUXLPBKT-UHFFFAOYSA-N 0.000 claims 2
• YHFNNGKIGBCQCZ-UHFFFAOYSA-N 1-[4-[4-[4-(methoxycarbonylamino)-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound COC(=O)NC1=C(C)ON=C1C1=CC=C(C=2C=CC(=CC=2)C2(CC2)C(O)=O)C=C1 YHFNNGKIGBCQCZ-UHFFFAOYSA-N 0.000 claims 2
• UQXZHDDPDJKDCZ-UHFFFAOYSA-N 1-[4-[4-[4-[1-(2-methoxyphenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound COC1=CC=CC=C1C(C)OC(=O)NC1=C(C)ON=C1C1=CC=C(C=2C=CC(=CC=2)C2(CC2)C(O)=O)C=C1 UQXZHDDPDJKDCZ-UHFFFAOYSA-N 0.000 claims 2
• QLACUASHTJHMSW-UHFFFAOYSA-N 1-[4-[4-[4-[1-(3-cyanophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C=CC(C#N)=CC=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 QLACUASHTJHMSW-UHFFFAOYSA-N 0.000 claims 2
• PAKRVYWEZJKCLX-QGZVFWFLSA-N 1-[4-[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 PAKRVYWEZJKCLX-QGZVFWFLSA-N 0.000 claims 2
• AUKRJBCKUBHNMI-GOSISDBHSA-N 1-[4-[4-[4-[[(1r)-1-(2-cyanophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)C#N)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 AUKRJBCKUBHNMI-GOSISDBHSA-N 0.000 claims 2
• KSJUWJUNCKLGKJ-GOSISDBHSA-N 1-[4-[4-[4-[[(1r)-1-(3-methoxyphenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound COC1=CC=CC([C@@H](C)OC(=O)NC=2C(=NOC=2C)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C2(CC2)C(O)=O)=C1 KSJUWJUNCKLGKJ-GOSISDBHSA-N 0.000 claims 2
• RQIHXXQULWXDPD-GOSISDBHSA-N 1-[4-[4-[4-[[(1r)-1-(4-methoxyphenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound C1=CC(OC)=CC=C1[C@@H](C)OC(=O)NC1=C(C)ON=C1C1=CC=C(C=2C=CC(=CC=2)C2(CC2)C(O)=O)C=C1 RQIHXXQULWXDPD-GOSISDBHSA-N 0.000 claims 2
• QFDDVZYHFZVIFU-MRXNPFEDSA-N 1-[4-[4-[4-[[(1r)-1-cyclobutylethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C1CCC1)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 QFDDVZYHFZVIFU-MRXNPFEDSA-N 0.000 claims 2
• KONCWDVFUVRDMU-QGZVFWFLSA-N 1-[4-[4-[4-[[(2r)-3,3-dimethylbutan-2-yl]oxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound CC(C)(C)[C@@H](C)OC(=O)NC1=C(C)ON=C1C1=CC=C(C=2C=CC(=CC=2)C2(CC2)C(O)=O)C=C1 KONCWDVFUVRDMU-QGZVFWFLSA-N 0.000 claims 2
• KEMCYAQORZMSGE-UHFFFAOYSA-N 1-[4-[4-[5-methyl-4-(1-phenylethoxycarbonylamino)-1,2-oxazol-3-yl]phenoxy]phenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C=CC=CC=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1OC(C=C1)=CC=C1C1(C(O)=O)CC1 KEMCYAQORZMSGE-UHFFFAOYSA-N 0.000 claims 2
• SUOYRXSKHXLEDC-UHFFFAOYSA-N 1-[4-[4-[5-methyl-4-(1-pyrazin-2-ylethoxycarbonylamino)-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound C=1N=CC=NC=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 SUOYRXSKHXLEDC-UHFFFAOYSA-N 0.000 claims 2
• ANQOWCCVEFRMMX-UHFFFAOYSA-N 1-[4-[4-[5-methyl-4-(2-phenylpropan-2-yloxycarbonylamino)-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound CC=1ON=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C2(CC2)C(O)=O)C=1NC(=O)OC(C)(C)C1=CC=CC=C1 ANQOWCCVEFRMMX-UHFFFAOYSA-N 0.000 claims 2
• GLGVPYOYFUCHCB-UHFFFAOYSA-N 1-[4-[4-[5-methyl-4-(phenylmethoxycarbonylamino)-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound CC=1ON=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C2(CC2)C(O)=O)C=1NC(=O)OCC1=CC=CC=C1 GLGVPYOYFUCHCB-UHFFFAOYSA-N 0.000 claims 2
• FQTXKQZWLUTAHT-UHFFFAOYSA-N 1-[4-[4-[5-methyl-4-(propan-2-yloxycarbonylamino)-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound CC(C)OC(=O)NC1=C(C)ON=C1C1=CC=C(C=2C=CC(=CC=2)C2(CC2)C(O)=O)C=C1 FQTXKQZWLUTAHT-UHFFFAOYSA-N 0.000 claims 2
• UDOVTTSBJPJRCL-UHFFFAOYSA-N 1-[4-[4-[5-methyl-4-[1-[4-(trifluoromethyl)phenyl]ethoxycarbonylamino]-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C=C(C(F)(F)F)C=CC=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 UDOVTTSBJPJRCL-UHFFFAOYSA-N 0.000 claims 2
• UQMQYXBVLXXFIW-LJQANCHMSA-N 1-[4-[4-[5-methyl-4-[[(1r)-1-(2-methylphenyl)ethoxy]carbonylamino]-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)C)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 UQMQYXBVLXXFIW-LJQANCHMSA-N 0.000 claims 2
• FEOFMGBTMIXBAD-LJQANCHMSA-N 1-[4-[4-[5-methyl-4-[[(1r)-1-(3-methylphenyl)ethoxy]carbonylamino]-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C=C(C)C=CC=1)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 FEOFMGBTMIXBAD-LJQANCHMSA-N 0.000 claims 2
• AEYYBRANOZMSPA-QGZVFWFLSA-N 1-[4-[4-[5-methyl-4-[[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]carbonylamino]-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)C(F)(F)F)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 AEYYBRANOZMSPA-QGZVFWFLSA-N 0.000 claims 2
• KEMCYAQORZMSGE-GOSISDBHSA-N 1-[4-[4-[5-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-3-yl]phenoxy]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C=CC=CC=1)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1OC(C=C1)=CC=C1C1(C(O)=O)CC1 KEMCYAQORZMSGE-GOSISDBHSA-N 0.000 claims 2
• WBGPXUNBQGMPRK-LJQANCHMSA-N 1-[4-[4-[5-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-3-yl]phenyl]phenyl]cyclobutane-1-carboxylic acid Chemical compound O([C@H](C)C=1C=CC=CC=1)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CCC1 WBGPXUNBQGMPRK-LJQANCHMSA-N 0.000 claims 2
• CYNRAOWZWAHONU-HXUWFJFHSA-N 1-[4-[4-[5-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-3-yl]phenyl]phenyl]cyclopentane-1-carboxylic acid Chemical compound O([C@H](C)C=1C=CC=CC=1)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CCCC1 CYNRAOWZWAHONU-HXUWFJFHSA-N 0.000 claims 2
• UUIOFIANMNWRJK-GOSISDBHSA-N 1-[4-[4-[5-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C=CC=CC=1)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 UUIOFIANMNWRJK-GOSISDBHSA-N 0.000 claims 2
• LHAKWYHIHXLEKL-CYBMUJFWSA-N 2-[2-[4-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]-1,3-thiazol-2-yl]phenyl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(N=1)=CSC=1C1=CC=CC=C1CC(O)=O LHAKWYHIHXLEKL-CYBMUJFWSA-N 0.000 claims 2
• ICHVPLBCVOZVSU-MRXNPFEDSA-N 2-[2-[4-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]sulfanylphenyl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1SC1=CC=CC=C1CC(O)=O ICHVPLBCVOZVSU-MRXNPFEDSA-N 0.000 claims 2
• LKSROZNQOKESMA-QGZVFWFLSA-N 2-[2-[4-[5-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-3-yl]phenyl]phenyl]acetic acid Chemical compound O([C@H](C)C=1C=CC=CC=1)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=CC=C1CC(O)=O LKSROZNQOKESMA-QGZVFWFLSA-N 0.000 claims 2
• QTZZROJDHUBSEE-UHFFFAOYSA-N 2-[2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methoxy]phenyl]acetic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1COC1=CC=CC=C1CC(O)=O QTZZROJDHUBSEE-UHFFFAOYSA-N 0.000 claims 2
• SQSZLPOGHAWFDF-UHFFFAOYSA-N 2-[3-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]-4-fluorophenyl]acetic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC(CC(O)=O)=CC=C1F SQSZLPOGHAWFDF-UHFFFAOYSA-N 0.000 claims 2
• BDGJXIZTNIOUFV-UHFFFAOYSA-N 2-[3-[4-[4-[1-(2-fluorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenoxy]phenyl]acetic acid Chemical compound C=1C=CC=C(F)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1OC1=CC=CC(CC(O)=O)=C1 BDGJXIZTNIOUFV-UHFFFAOYSA-N 0.000 claims 2
• GXTZBFHPXXZCFC-MRXNPFEDSA-N 2-[3-[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenoxy]phenyl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1OC1=CC=CC(CC(O)=O)=C1 GXTZBFHPXXZCFC-MRXNPFEDSA-N 0.000 claims 2
• HBKDJQRLQZUSSX-CYBMUJFWSA-N 2-[3-[4-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]-1,3-thiazol-2-yl]phenyl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(N=1)=CSC=1C1=CC=CC(CC(O)=O)=C1 HBKDJQRLQZUSSX-CYBMUJFWSA-N 0.000 claims 2
• FBJJGGDZAXGORA-MRXNPFEDSA-N 2-[3-[4-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]sulfanylphenyl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1SC1=CC=CC(CC(O)=O)=C1 FBJJGGDZAXGORA-MRXNPFEDSA-N 0.000 claims 2
• NPACGXSQIUJGTJ-QGZVFWFLSA-N 2-[3-[4-[5-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-3-yl]phenyl]phenyl]acetic acid Chemical compound O([C@H](C)C=1C=CC=CC=1)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=CC(CC(O)=O)=C1 NPACGXSQIUJGTJ-QGZVFWFLSA-N 0.000 claims 2
• MSLBJICXPHPALI-UHFFFAOYSA-N 2-[3-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methyl]phenyl]acetic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1CC1=CC=CC(CC(O)=O)=C1 MSLBJICXPHPALI-UHFFFAOYSA-N 0.000 claims 2
• IJRMMVBFZVJAAS-UHFFFAOYSA-N 2-[3-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methylsulfonyl]phenyl]acetic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1CS(=O)(=O)C1=CC=CC(CC(O)=O)=C1 IJRMMVBFZVJAAS-UHFFFAOYSA-N 0.000 claims 2
• LHHCWDJUFLRMSJ-QGZVFWFLSA-N 2-[3-[[4-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methyl]phenyl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1CC1=CC=CC(CC(O)=O)=C1 LHHCWDJUFLRMSJ-QGZVFWFLSA-N 0.000 claims 2
• OCVBMTVEVXKSLI-OAHLLOKOSA-N 2-[4-[2-chloro-4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(C)ON=C1C(C=C1Cl)=CC=C1C1=CC=C(CC(O)=O)C=C1 OCVBMTVEVXKSLI-OAHLLOKOSA-N 0.000 claims 2
• HMCABEARYUIMAL-OAHLLOKOSA-N 2-[4-[3-chloro-4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(C)ON=C1C(C(=C1)Cl)=CC=C1C1=CC=C(CC(O)=O)C=C1 HMCABEARYUIMAL-OAHLLOKOSA-N 0.000 claims 2
• DNOWPFLHVDBRSW-UHFFFAOYSA-N 2-[4-[4-[4-[1-(2,3-difluorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]acetic acid Chemical compound C=1C=CC(F)=C(F)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(CC(O)=O)C=C1 DNOWPFLHVDBRSW-UHFFFAOYSA-N 0.000 claims 2
• UIFMNDYVKMBUNB-UHFFFAOYSA-N 2-[4-[4-[4-[1-(2,6-difluorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]acetic acid Chemical compound FC=1C=CC=C(F)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(CC(O)=O)C=C1 UIFMNDYVKMBUNB-UHFFFAOYSA-N 0.000 claims 2
• OIPIOGBLKYRDIU-UHFFFAOYSA-N 2-[4-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]propanoic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(C(C)C(O)=O)C=C1 OIPIOGBLKYRDIU-UHFFFAOYSA-N 0.000 claims 2
• JZGDATWSMIDXEA-UHFFFAOYSA-N 2-[4-[4-[4-[1-(2-fluorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]-2-methylpropanoic acid Chemical compound C=1C=CC=C(F)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(C(C)(C)C(O)=O)C=C1 JZGDATWSMIDXEA-UHFFFAOYSA-N 0.000 claims 2
• NLUAABYBJYQYKT-UHFFFAOYSA-N 2-[4-[4-[4-[1-(2-fluorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]propanoic acid Chemical compound C=1C=CC=C(F)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(C(C)C(O)=O)C=C1 NLUAABYBJYQYKT-UHFFFAOYSA-N 0.000 claims 2
• SOZPXFQIVKKUGZ-QGZVFWFLSA-N 2-[4-[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]-2-methylpropanoic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(C(C)(C)C(O)=O)C=C1 SOZPXFQIVKKUGZ-QGZVFWFLSA-N 0.000 claims 2
• COBYXCXDUVTKFP-LIXIDFRTSA-N 2-[4-[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]butanoic acid Chemical compound C1=CC(C(C(O)=O)CC)=CC=C1C1=CC=C(C=2C(=C(C)ON=2)NC(=O)O[C@H](C)C=2C(=CC=CC=2)Cl)C=C1 COBYXCXDUVTKFP-LIXIDFRTSA-N 0.000 claims 2
• IZQCMHUHINPDDF-CYBMUJFWSA-N 2-[4-[4-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]-1,3-thiazol-2-yl]phenyl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(N=1)=CSC=1C1=CC=C(CC(O)=O)C=C1 IZQCMHUHINPDDF-CYBMUJFWSA-N 0.000 claims 2
• YMWKAZHGWHSZEV-QRWMCTBCSA-N 2-[4-[4-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]-2-methylphenyl]phenyl]propanoic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(C=C1C)=CC=C1C1=CC=C(C(C)C(O)=O)C=C1 YMWKAZHGWHSZEV-QRWMCTBCSA-N 0.000 claims 2
• CQKMDHILFWVVEJ-FXBVVIMESA-N 2-[4-[4-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]-2-hydroxyacetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(C(O)C(O)=O)C=C1 CQKMDHILFWVVEJ-FXBVVIMESA-N 0.000 claims 2
• CAIXJNGREPLJPB-MRXNPFEDSA-N 2-[4-[4-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(CC(O)=O)C=C1 CAIXJNGREPLJPB-MRXNPFEDSA-N 0.000 claims 2
• NLUAABYBJYQYKT-ZYMOGRSISA-N 2-[4-[4-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]propanoic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(C(C)C(O)=O)C=C1 NLUAABYBJYQYKT-ZYMOGRSISA-N 0.000 claims 2
• HHTGDDRDWUWWLN-MRXNPFEDSA-N 2-[4-[4-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]sulfanylphenyl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1SC1=CC=C(CC(O)=O)C=C1 HHTGDDRDWUWWLN-MRXNPFEDSA-N 0.000 claims 2
• VTOLOLFIARHIQS-INIZCTEOSA-N 2-[4-[4-[4-[[(1s)-1-(2-chlorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]acetic acid Chemical compound O([C@@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(CC(O)=O)C=C1 VTOLOLFIARHIQS-INIZCTEOSA-N 0.000 claims 2
• CAIXJNGREPLJPB-INIZCTEOSA-N 2-[4-[4-[4-[[(1s)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]acetic acid Chemical compound O([C@@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(CC(O)=O)C=C1 CAIXJNGREPLJPB-INIZCTEOSA-N 0.000 claims 2
• YXUPKMKYXSZDHZ-GOSISDBHSA-N 2-[4-[4-[5-methyl-4-[[(1r)-1-(2-methylphenyl)ethoxy]carbonylamino]-1,2-oxazol-3-yl]phenyl]phenyl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)C)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(CC(O)=O)C=C1 YXUPKMKYXSZDHZ-GOSISDBHSA-N 0.000 claims 2
• PNUVDGKGKXWASR-CYBMUJFWSA-N 2-[4-[5-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]-1,3-thiazol-2-yl]phenyl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(S1)=CN=C1C1=CC=C(CC(O)=O)C=C1 PNUVDGKGKXWASR-CYBMUJFWSA-N 0.000 claims 2
• WTZXRUIRDPQNBR-UHFFFAOYSA-N 2-[4-[6-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]pyridin-3-yl]phenyl]acetic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(N=C1)=CC=C1C1=CC=C(CC(O)=O)C=C1 WTZXRUIRDPQNBR-UHFFFAOYSA-N 0.000 claims 2
• BOAMWHKMHAWUBE-UHFFFAOYSA-N 2-[4-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methyl]phenyl]acetic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1CC1=CC=C(CC(O)=O)C=C1 BOAMWHKMHAWUBE-UHFFFAOYSA-N 0.000 claims 2
• WNKDDEOCVYNIJH-UHFFFAOYSA-N 2-[4-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methylsulfonyl]phenyl]acetic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1CS(=O)(=O)C1=CC=C(CC(O)=O)C=C1 WNKDDEOCVYNIJH-UHFFFAOYSA-N 0.000 claims 2
• QBOKCUFZFCALQX-QGZVFWFLSA-N 2-[4-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methoxy]phenyl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1COC1=CC=C(CC(O)=O)C=C1 QBOKCUFZFCALQX-QGZVFWFLSA-N 0.000 claims 2
• FYXNUNOICCOJKT-UHFFFAOYSA-N 2-[5-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]pyridin-3-yl]acetic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CN=CC(CC(O)=O)=C1 FYXNUNOICCOJKT-UHFFFAOYSA-N 0.000 claims 2
• KLQZPEUOQAEWDW-UHFFFAOYSA-N 2-[6-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]pyridin-3-yl]acetic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(CC(O)=O)C=N1 KLQZPEUOQAEWDW-UHFFFAOYSA-N 0.000 claims 2
• SLZGXMJAWDJHQM-OAHLLOKOSA-N 2-[6-[4-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]sulfanylpyridin-3-yl]acetic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1SC1=CC=C(CC(O)=O)C=N1 SLZGXMJAWDJHQM-OAHLLOKOSA-N 0.000 claims 2
• PNCNYZLSMZXBGX-UHFFFAOYSA-N 3-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]benzoic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=CC(C(O)=O)=C1 PNCNYZLSMZXBGX-UHFFFAOYSA-N 0.000 claims 2
• FIPWLWTWDQTUCA-UHFFFAOYSA-N 3-[4-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]propanoic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(CCC(O)=O)C=C1 FIPWLWTWDQTUCA-UHFFFAOYSA-N 0.000 claims 2
• KGOCGOARWWJYCH-UHFFFAOYSA-N 3-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methyl]imidazole-4-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1CN1C=NC=C1C(O)=O KGOCGOARWWJYCH-UHFFFAOYSA-N 0.000 claims 2
• NXWNZVYNYWNVGC-UHFFFAOYSA-N 4-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]cyclohex-3-ene-1-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CCC(C(O)=O)CC1 NXWNZVYNYWNVGC-UHFFFAOYSA-N 0.000 claims 2
• UDEHKDMFTIVCRJ-UHFFFAOYSA-N 4-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]cyclohexane-1-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1CCC(C(O)=O)CC1 UDEHKDMFTIVCRJ-UHFFFAOYSA-N 0.000 claims 2
• QVQNJNNGWXPBHZ-UHFFFAOYSA-N 4-[4-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]butanoic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(CCCC(O)=O)C=C1 QVQNJNNGWXPBHZ-UHFFFAOYSA-N 0.000 claims 2
• VHBATFRPLJDCNN-OAHLLOKOSA-N 4-[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]benzoic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(C(O)=O)C=C1 VHBATFRPLJDCNN-OAHLLOKOSA-N 0.000 claims 2
• KHEIXGXOOTVYNG-MRXNPFEDSA-N 4-[[4-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenoxy]methyl]benzoic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1OCC1=CC=C(C(O)=O)C=C1 KHEIXGXOOTVYNG-MRXNPFEDSA-N 0.000 claims 2
• BUYAJOKDUPTFGK-QGZVFWFLSA-N [(1R)-1-(2-fluorophenyl)ethyl] N-[3-[4-[4-(2-acetamido-2-iminoethyl)phenyl]phenyl]-5-methyl-1,2-oxazol-4-yl]carbamate Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(CC(=N)NC(C)=O)C=C1 BUYAJOKDUPTFGK-QGZVFWFLSA-N 0.000 claims 2
• XABWVJCDBGXRSI-MRXNPFEDSA-N [(1R)-1-(2-fluorophenyl)ethyl] N-[3-[4-[4-(2-amino-2-iminoethyl)phenyl]phenyl]-5-methyl-1,2-oxazol-4-yl]carbamate Chemical compound O([C@H](C)C=1C(=CC=CC=1)F)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(CC(N)=N)C=C1 XABWVJCDBGXRSI-MRXNPFEDSA-N 0.000 claims 2
• LTWVZLZIDSRILG-LJQANCHMSA-N [(1r)-1-phenylethyl] n-[3-[4-[4-(dimethoxyphosphorylmethyl)phenyl]phenyl]-5-methyl-1,2-oxazol-4-yl]carbamate Chemical compound C1=CC(CP(=O)(OC)OC)=CC=C1C1=CC=C(C=2C(=C(C)ON=2)NC(=O)O[C@H](C)C=2C=CC=CC=2)C=C1 LTWVZLZIDSRILG-LJQANCHMSA-N 0.000 claims 2
• VZDAGSFPGLYODC-UHFFFAOYSA-N ethyl 2-[4-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]propanoate Chemical compound C1=CC(C(C)C(=O)OCC)=CC=C1C1=CC=C(C=2C(=C(C)ON=2)NC(=O)OC(C)C=2C(=CC=CC=2)Cl)C=C1 VZDAGSFPGLYODC-UHFFFAOYSA-N 0.000 claims 2
• LLCBIXIGWLDLIZ-GOSISDBHSA-N ethyl 2-[4-[4-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenoxy]phenyl]acetate Chemical compound C1=CC(CC(=O)OCC)=CC=C1OC1=CC=C(C=2C(=C(C)ON=2)NC(=O)O[C@H](C)C=2C(=CC=CC=2)F)C=C1 LLCBIXIGWLDLIZ-GOSISDBHSA-N 0.000 claims 2
• 238000001802 infusion Methods 0.000 claims 2
• RKPIIFMVOMWBQO-CYBMUJFWSA-N methyl 2-[5-[4-[4-[[(1r)-1-(2-fluorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]tetrazol-2-yl]acetate Chemical compound COC(=O)CN1N=NC(C=2C=CC(=CC=2)C=2C(=C(C)ON=2)NC(=O)O[C@H](C)C=2C(=CC=CC=2)F)=N1 RKPIIFMVOMWBQO-CYBMUJFWSA-N 0.000 claims 2
• VJLYHTOSFSGXGH-CQSZACIVSA-N (2R)-1-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2[C@H](CCC2)C(=O)O)C=CC=1 VJLYHTOSFSGXGH-CQSZACIVSA-N 0.000 claims 1
• ZXAQFYZQHPGMMN-BZSJEYESSA-N (3R)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylcyclohexane-1-carboxamide Chemical compound C1C[C@H](CC(C1)C(=O)NC2=CC=CC=C2)OC3=CC(=CC(=N3)C(F)(F)F)CN ZXAQFYZQHPGMMN-BZSJEYESSA-N 0.000 claims 1
• ZWHOTPNCEFWATE-CQSZACIVSA-N (3R)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpyrrolidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@H]1CN(CC1)C(=O)NC1=CC=CC=C1 ZWHOTPNCEFWATE-CQSZACIVSA-N 0.000 claims 1
• ZWHOTPNCEFWATE-AWEZNQCLSA-N (3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpyrrolidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CC1)C(=O)NC1=CC=CC=C1 ZWHOTPNCEFWATE-AWEZNQCLSA-N 0.000 claims 1
• SNAKUPLQASYKTC-AWEZNQCLSA-N (3S)-3-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]-N-phenylpiperidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC[C@@H]1CN(CCC1)C(=O)NC1=CC=CC=C1 SNAKUPLQASYKTC-AWEZNQCLSA-N 0.000 claims 1
• RAVIQFQJZMTUBX-AWEZNQCLSA-N 1-[(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-2-(3,4-dichlorophenyl)ethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(CC1=CC(=C(C=C1)Cl)Cl)=O RAVIQFQJZMTUBX-AWEZNQCLSA-N 0.000 claims 1
• XAOMFUPJQYNDEG-LBPRGKRZSA-N 1-[(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-2-methylpropan-1-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(C(C)C)=O XAOMFUPJQYNDEG-LBPRGKRZSA-N 0.000 claims 1
• JZSHKZABPPZQLV-UHFFFAOYSA-N 1-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]pyridin-2-one Chemical compound NCC1=CC(OC2=CC=CC(=C2)N2C=CC=CC2=O)=NC(=C1)C(F)(F)F JZSHKZABPPZQLV-UHFFFAOYSA-N 0.000 claims 1
• KHKQQQLOLBEJES-UHFFFAOYSA-N 1-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]pyridin-2-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)N1C(C=CC=C1)=O KHKQQQLOLBEJES-UHFFFAOYSA-N 0.000 claims 1
• KJJYKTPTWOMQBQ-UHFFFAOYSA-N 1-[4-[4-[5-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1=C(C)ON=C1C1=CC=C(C=2C=CC(=CC=2)C2(CC2)C(O)=O)C=C1 KJJYKTPTWOMQBQ-UHFFFAOYSA-N 0.000 claims 1
• VXAFFDNJPRCPMM-LJQANCHMSA-N 1-[4-[4-[5-methyl-4-[[(1r)-1-(4-methylphenyl)ethoxy]carbonylamino]-1,2-oxazol-3-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C=CC(C)=CC=1)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 VXAFFDNJPRCPMM-LJQANCHMSA-N 0.000 claims 1
• QJQGFIUCAQOASM-UHFFFAOYSA-N 1-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methyl]-1,2,4-triazole-3-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1CN1C=NC(C(O)=O)=N1 QJQGFIUCAQOASM-UHFFFAOYSA-N 0.000 claims 1
• FZZKXHLEIKNESO-UHFFFAOYSA-N 1-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methyl]imidazole-4-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1CN1C=NC(C(O)=O)=C1 FZZKXHLEIKNESO-UHFFFAOYSA-N 0.000 claims 1
• WWESTBCNCBYVAH-UHFFFAOYSA-N 1-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1CN1C=C(C(O)=O)C=N1 WWESTBCNCBYVAH-UHFFFAOYSA-N 0.000 claims 1
• RNIUHIHTGPHJEN-AWEZNQCLSA-N 2-[(3S)-1-[2-(3,4-dichlorophenyl)acetyl]piperidin-3-yl]oxy-6-(trifluoromethyl)pyridine-4-carbonitrile Chemical compound ClC=1C=C(C=CC=1Cl)CC(=O)N1C[C@H](CCC1)OC=1C=C(C#N)C=C(N=1)C(F)(F)F RNIUHIHTGPHJEN-AWEZNQCLSA-N 0.000 claims 1
• DCGQVDFBDSTUML-AWEZNQCLSA-N 2-[(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidine-1-carbonyl]chromen-4-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1OC2=CC=CC=C2C(C=1)=O DCGQVDFBDSTUML-AWEZNQCLSA-N 0.000 claims 1
• APDYPEOKIUKUQV-UHFFFAOYSA-N 2-[1-(2-oxo-2-piperidin-1-ylethyl)indol-4-yl]oxy-6-(trifluoromethyl)pyridine-4-carbonitrile Chemical compound O=C(CN1C=CC2=C(C=CC=C12)OC=1C=C(C#N)C=C(N=1)C(F)(F)F)N1CCCCC1 APDYPEOKIUKUQV-UHFFFAOYSA-N 0.000 claims 1
• MBBVINHIEJNJHZ-UHFFFAOYSA-N 2-[2-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]acetic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=CC=C1CC(O)=O MBBVINHIEJNJHZ-UHFFFAOYSA-N 0.000 claims 1
• XDNUQPIVYCJLNG-UHFFFAOYSA-N 2-[2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methyl]phenyl]acetic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1CC1=CC=CC=C1CC(O)=O XDNUQPIVYCJLNG-UHFFFAOYSA-N 0.000 claims 1
• KZJYFEKWPFNHEN-UHFFFAOYSA-N 2-[3-[3-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]-4-fluorophenyl]acetic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=1)=CC=CC=1C1=CC(CC(O)=O)=CC=C1F KZJYFEKWPFNHEN-UHFFFAOYSA-N 0.000 claims 1
• AVCXOQNNCFFCDK-UHFFFAOYSA-N 2-[3-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]benzoic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=1)=CC=CC=1C1=CC=CC=C1C(O)=O AVCXOQNNCFFCDK-UHFFFAOYSA-N 0.000 claims 1
• WCGYSSHZESSPGO-UHFFFAOYSA-N 2-[3-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]pyridine-4-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=1)=CC=CC=1C1=CC(C(O)=O)=CC=N1 WCGYSSHZESSPGO-UHFFFAOYSA-N 0.000 claims 1
• RIWNJDYXFNNYMK-UHFFFAOYSA-N 2-[3-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]acetic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=CC(CC(O)=O)=C1 RIWNJDYXFNNYMK-UHFFFAOYSA-N 0.000 claims 1
• LUPXPXGWTGBSPV-UHFFFAOYSA-N 2-[3-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methyl]-4-methoxyphenyl]acetic acid Chemical compound COC1=CC=C(CC(O)=O)C=C1CC1=CC=C(C=2C(=C(C)ON=2)NC(=O)OC(C)C=2C(=CC=CC=2)Cl)C=C1 LUPXPXGWTGBSPV-UHFFFAOYSA-N 0.000 claims 1
• KTPPIIRRIKZBPJ-UHFFFAOYSA-N 2-[3-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methylsulfanyl]phenyl]acetic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1CSC1=CC=CC(CC(O)=O)=C1 KTPPIIRRIKZBPJ-UHFFFAOYSA-N 0.000 claims 1
• BVKRPQCDGACLPX-UHFFFAOYSA-N 2-[4-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyindol-1-yl]-N-methyl-N-phenylacetamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC1=C2C=CN(C2=CC=C1)CC(=O)N(C1=CC=CC=C1)C BVKRPQCDGACLPX-UHFFFAOYSA-N 0.000 claims 1
• AIOSOYCTGNJOCE-UHFFFAOYSA-N 2-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]benzoic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=CC=C1C(O)=O AIOSOYCTGNJOCE-UHFFFAOYSA-N 0.000 claims 1
• HRFQWNYYDHTNSX-UHFFFAOYSA-N 2-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]pyridine-4-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC(C(O)=O)=CC=N1 HRFQWNYYDHTNSX-UHFFFAOYSA-N 0.000 claims 1
• DOOXGEMWPVXYBQ-UHFFFAOYSA-N 2-[4-[4-[4-[1-(2,4-dichlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]acetic acid Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(CC(O)=O)C=C1 DOOXGEMWPVXYBQ-UHFFFAOYSA-N 0.000 claims 1
• FSUKLLHHCNWZFQ-UHFFFAOYSA-N 2-[4-[4-[4-[1-(2,6-dichlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]phenyl]acetic acid Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(CC(O)=O)C=C1 FSUKLLHHCNWZFQ-UHFFFAOYSA-N 0.000 claims 1
• MASQQWAXAJKJEO-UHFFFAOYSA-N 2-[4-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methylsulfanyl]phenyl]acetic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1CSC1=CC=C(CC(O)=O)C=C1 MASQQWAXAJKJEO-UHFFFAOYSA-N 0.000 claims 1
• JAAYKMDVVYEHKG-UHFFFAOYSA-N 2-[5-[3-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]-6-methoxypyridin-3-yl]acetic acid Chemical compound COC1=NC=C(CC(O)=O)C=C1C1=CC=CC(C=2C(=C(C)ON=2)NC(=O)OC(C)C=2C(=CC=CC=2)Cl)=C1 JAAYKMDVVYEHKG-UHFFFAOYSA-N 0.000 claims 1
• CJYDQTAWSHWBIT-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-hydroxy-2-methylpropyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC(C)(C)O)C=CC=1 CJYDQTAWSHWBIT-UHFFFAOYSA-N 0.000 claims 1
• SHBHYINHXNTBRP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-methylsulfonylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(=O)(=O)C)C=CC=1 SHBHYINHXNTBRP-UHFFFAOYSA-N 0.000 claims 1
• LIDBMZYKSAXTQG-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-sulfamoylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(N)(=O)=O)C=CC=1 LIDBMZYKSAXTQG-UHFFFAOYSA-N 0.000 claims 1
• VTNULXUEOJMRKZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2H-tetrazol-5-ylmethyl)benzamide Chemical compound N=1NN=NC=1CNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O VTNULXUEOJMRKZ-UHFFFAOYSA-N 0.000 claims 1
• GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 claims 1
• ISXSUKUXUPLGTD-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(5-oxopyrrolidin-2-yl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2NC(CC2)=O)C=CC=1 ISXSUKUXUPLGTD-UHFFFAOYSA-N 0.000 claims 1
• FJPUKTJEFOXMJX-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[1-(hydroxymethyl)cyclopropyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2(CC2)CO)C=CC=1 FJPUKTJEFOXMJX-UHFFFAOYSA-N 0.000 claims 1
• ZMCQQCBOZIGNRV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(1,2,4-triazol-1-yl)ethyl]benzamide Chemical compound NCC1=CC(OC2=CC=CC(=C2)C(=O)NCCN2C=NC=N2)=NC(=C1)C(F)(F)F ZMCQQCBOZIGNRV-UHFFFAOYSA-N 0.000 claims 1
• FVQKGQNSCKJPIJ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCN2C(OCC2)=O)C=CC=1 FVQKGQNSCKJPIJ-UHFFFAOYSA-N 0.000 claims 1
• ZUNFPBNHELLPPP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(dimethylamino)ethyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCN(C)C)C=CC=1 ZUNFPBNHELLPPP-UHFFFAOYSA-N 0.000 claims 1
• AJZDHLHTTJRNQJ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(tetrazol-1-yl)ethyl]benzamide Chemical compound N1(N=NN=C1)CCNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O AJZDHLHTTJRNQJ-UHFFFAOYSA-N 0.000 claims 1
• MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 claims 1
• HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 claims 1
• UNVNJEAVDWBGJW-UHFFFAOYSA-N 3-[4-[4-(2,3-dihydro-1h-inden-1-yloxycarbonylamino)-5-methyl-1,2-oxazol-3-yl]phenyl]benzoic acid Chemical compound C1CC2=CC=CC=C2C1OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=CC(C(O)=O)=C1 UNVNJEAVDWBGJW-UHFFFAOYSA-N 0.000 claims 1
• SZDYEAVTZRWNJD-UHFFFAOYSA-N 3-[4-[5-methyl-4-[(6-methylpyridin-2-yl)methoxycarbonylamino]-1,2-oxazol-3-yl]phenyl]benzoic acid Chemical compound CC=1ON=C(C=2C=CC(=CC=2)C=2C=C(C=CC=2)C(O)=O)C=1NC(=O)OCC1=CC=CC(C)=N1 SZDYEAVTZRWNJD-UHFFFAOYSA-N 0.000 claims 1
• DASDZZQLNSVETF-OAHLLOKOSA-N 3-[4-[5-methyl-4-[[(1r)-1-pyridin-2-ylethoxy]carbonylamino]-1,2-oxazol-3-yl]phenyl]benzoic acid Chemical compound O([C@H](C)C=1N=CC=CC=1)C(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=CC(C(O)=O)=C1 DASDZZQLNSVETF-OAHLLOKOSA-N 0.000 claims 1
• UBZNSCWVHXALMQ-UHFFFAOYSA-N 3-[[4-[4-[(2-bromophenyl)methoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methyl]benzoic acid Chemical compound CC=1ON=C(C=2C=CC(CC=3C=C(C=CC=3)C(O)=O)=CC=2)C=1NC(=O)OCC1=CC=CC=C1Br UBZNSCWVHXALMQ-UHFFFAOYSA-N 0.000 claims 1
• LLOSAJZYBTUNMO-UHFFFAOYSA-N 3-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methoxy]benzoic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1COC1=CC=CC(C(O)=O)=C1 LLOSAJZYBTUNMO-UHFFFAOYSA-N 0.000 claims 1
• SNHCICBHHCNISG-UHFFFAOYSA-N 3-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methyl]benzoic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1CC1=CC=CC(C(O)=O)=C1 SNHCICBHHCNISG-UHFFFAOYSA-N 0.000 claims 1
• OIBZMMPOWDEASK-UHFFFAOYSA-N 3-[[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]amino]methyl]-N-(2-methylsulfonylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)NCC=1C=C(C(=O)NCCS(=O)(=O)C)C=CC=1 OIBZMMPOWDEASK-UHFFFAOYSA-N 0.000 claims 1
• XXAFCSLVTWGVEY-UHFFFAOYSA-N 3-[[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]amino]methyl]-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)NCC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 XXAFCSLVTWGVEY-UHFFFAOYSA-N 0.000 claims 1
• PDVCWOGMWFGYGQ-UHFFFAOYSA-N 4-[3-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]cyclohex-3-ene-1-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=1)=CC=CC=1C1=CCC(C(O)=O)CC1 PDVCWOGMWFGYGQ-UHFFFAOYSA-N 0.000 claims 1
• QEIVWSRXBYOTAZ-UHFFFAOYSA-N 4-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpiperidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC1CCN(CC1)C(=O)NC1=CC=CC=C1 QEIVWSRXBYOTAZ-UHFFFAOYSA-N 0.000 claims 1
• VHBATFRPLJDCNN-UHFFFAOYSA-N 4-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]benzoic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(C(O)=O)C=C1 VHBATFRPLJDCNN-UHFFFAOYSA-N 0.000 claims 1
• KSLLGMKWOPGVEB-UHFFFAOYSA-N 4-[4-[5-methyl-4-(propan-2-yloxycarbonylamino)-1,2-oxazol-3-yl]phenyl]benzoic acid Chemical compound CC(C)OC(=O)NC1=C(C)ON=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 KSLLGMKWOPGVEB-UHFFFAOYSA-N 0.000 claims 1
• HOWFLZVASJDZRZ-UHFFFAOYSA-N 4-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]-N-phenylpiperidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OCC1CCN(CC1)C(=O)NC1=CC=CC=C1 HOWFLZVASJDZRZ-UHFFFAOYSA-N 0.000 claims 1
• PDWCIZAWHUHZMP-UHFFFAOYSA-N 4-chloro-3-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methyl]benzoic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1CC1=CC(C(O)=O)=CC=C1Cl PDWCIZAWHUHZMP-UHFFFAOYSA-N 0.000 claims 1
• DILGAIKMSYWDTG-UHFFFAOYSA-N 5-[3-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]pyridine-2-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=1)=CC=CC=1C1=CC=C(C(O)=O)N=C1 DILGAIKMSYWDTG-UHFFFAOYSA-N 0.000 claims 1
• YGYKQXTZQGYHAA-UHFFFAOYSA-N 5-[3-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]pyridine-3-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=1)=CC=CC=1C1=CN=CC(C(O)=O)=C1 YGYKQXTZQGYHAA-UHFFFAOYSA-N 0.000 claims 1
• FOFSNCRMWLKAIM-UHFFFAOYSA-N 5-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-3,4-dihydro-1H-quinolin-2-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC1=C2CCC(NC2=CC=C1)=O FOFSNCRMWLKAIM-UHFFFAOYSA-N 0.000 claims 1
• ZFYXJIYPIORSQE-UHFFFAOYSA-N 5-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-methylsulfonylethyl)pyridine-3-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=NC=C(C(=O)NCCS(=O)(=O)C)C=1 ZFYXJIYPIORSQE-UHFFFAOYSA-N 0.000 claims 1
• KEQRKIKNANGWQR-UHFFFAOYSA-N 5-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]pyridine-2-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(C(O)=O)N=C1 KEQRKIKNANGWQR-UHFFFAOYSA-N 0.000 claims 1
• DNAKHRCEDATCDH-UHFFFAOYSA-N 5-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]pyridine-3-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CN=CC(C(O)=O)=C1 DNAKHRCEDATCDH-UHFFFAOYSA-N 0.000 claims 1
• AYJWGMHRKWHEQQ-UHFFFAOYSA-N 5-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methyl]thiophene-2-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1CC1=CC=C(C(O)=O)S1 AYJWGMHRKWHEQQ-UHFFFAOYSA-N 0.000 claims 1
• SHRQMIRYBMSZBE-UHFFFAOYSA-N 6-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]pyridine-2-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=CC(C(O)=O)=N1 SHRQMIRYBMSZBE-UHFFFAOYSA-N 0.000 claims 1
• LHWCWLMJFRPTEX-UHFFFAOYSA-N 6-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]pyridine-3-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC1=C(C)ON=C1C(C=C1)=CC=C1C1=CC=C(C(O)=O)C=N1 LHWCWLMJFRPTEX-UHFFFAOYSA-N 0.000 claims 1
• NRLQBVLOUUPAMI-UHFFFAOYSA-N 8-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2CCC3(CNC(O3)=O)CC2)C=CC=1 NRLQBVLOUUPAMI-UHFFFAOYSA-N 0.000 claims 1
• 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
• 229940122849 Autotaxin inhibitor Drugs 0.000 claims 1
• 208000008720 Bone Marrow Neoplasms Diseases 0.000 claims 1
• 206010005949 Bone cancer Diseases 0.000 claims 1
• 208000018084 Bone neoplasm Diseases 0.000 claims 1
• LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 claims 1
• 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
• 208000033626 Renal failure acute Diseases 0.000 claims 1
• 208000034189 Sclerosis Diseases 0.000 claims 1
• 206010050207 Skin fibrosis Diseases 0.000 claims 1
• GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
• 206010052779 Transplant rejections Diseases 0.000 claims 1
• JDCLUYDBENDDSR-NSHDSACASA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-(5-methyl-1,3,4-oxadiazol-2-yl)methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1OC(=NN=1)C JDCLUYDBENDDSR-NSHDSACASA-N 0.000 claims 1
• RWQJLIWMOBYOTI-AWEZNQCLSA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-pyridin-3-ylmethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1C=NC=CC=1 RWQJLIWMOBYOTI-AWEZNQCLSA-N 0.000 claims 1
• WGCOQYDRMPFAMN-ZDUSSCGKSA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-pyrimidin-5-ylmethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1C=NC=NC=1 WGCOQYDRMPFAMN-ZDUSSCGKSA-N 0.000 claims 1
• PKZVFOVXYKCBCJ-UHFFFAOYSA-N [2-(1H-indol-4-yloxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1C=CC2=C(C=CC=C12)OC1=NC(=CC(=C1)CN)C(F)(F)F PKZVFOVXYKCBCJ-UHFFFAOYSA-N 0.000 claims 1
• ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 claims 1
• GXFIJNNOECYQOJ-UHFFFAOYSA-N [2-[1-(1-methylpyrazol-4-yl)indol-4-yl]oxy-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound CN1N=CC(=C1)N1C=CC2=C(C=CC=C12)OC1=NC(=CC(=C1)CN)C(F)(F)F GXFIJNNOECYQOJ-UHFFFAOYSA-N 0.000 claims 1
• REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 claims 1
• SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 claims 1
• ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 claims 1
• YQYBUJYBXOVWQW-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1CC2=CC=CC=C2CC1 YQYBUJYBXOVWQW-UHFFFAOYSA-N 0.000 claims 1
• YKKPYMXANSSQCA-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3-pyrazol-1-ylazetidin-1-yl)methanone Chemical compound N1(N=CC=C1)C1CN(C1)C(=O)C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F YKKPYMXANSSQCA-UHFFFAOYSA-N 0.000 claims 1
• JOSCNYCOYXTLTN-GFCCVEGCSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-(hydroxymethyl)pyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)CO JOSCNYCOYXTLTN-GFCCVEGCSA-N 0.000 claims 1
• BYWBCSRCPLBDFU-CYBMUJFWSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-aminopyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)N BYWBCSRCPLBDFU-CYBMUJFWSA-N 0.000 claims 1
• LJHFUFVRZNYVMK-CYBMUJFWSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-hydroxypyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)O LJHFUFVRZNYVMK-CYBMUJFWSA-N 0.000 claims 1
• LJHFUFVRZNYVMK-ZDUSSCGKSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3S)-3-hydroxypyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@H](CC1)O LJHFUFVRZNYVMK-ZDUSSCGKSA-N 0.000 claims 1
• JWSIZPAOIFLWKM-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[3-(dimethylamino)-4-hydroxypyrrolidin-1-yl]methanone Chemical compound CN(C)C1CN(CC1O)C(=O)c1cccc(Oc2cc(CN)cc(n2)C(F)(F)F)c1 JWSIZPAOIFLWKM-UHFFFAOYSA-N 0.000 claims 1
• KDSYNTPPPISIJB-UHFFFAOYSA-N [3-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]phenyl]-(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone Chemical compound NCc1cc(OCc2cccc(c2)C(=O)N2CC(O)C(F)C2)nc(c1)C(F)(F)F KDSYNTPPPISIJB-UHFFFAOYSA-N 0.000 claims 1
• UGKIKJFPXNOHHA-UHFFFAOYSA-N [5-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypyridin-3-yl]-(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=NC=1)C(=O)N1CC(C(C1)O)F UGKIKJFPXNOHHA-UHFFFAOYSA-N 0.000 claims 1
• IQUWAPNUQVLWGG-GFCCVEGCSA-N [5-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypyridin-3-yl]-[(3R)-3-aminopyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=NC=1)C(=O)N1C[C@@H](CC1)N IQUWAPNUQVLWGG-GFCCVEGCSA-N 0.000 claims 1
• JXUQCRSZQYGYQM-UHFFFAOYSA-N [5-methyl-3-[4-[4-(2h-tetrazol-5-ylmethyl)phenyl]phenyl]-1,2-oxazol-4-yl]carbamic acid Chemical compound OC(=O)NC1=C(C)ON=C1C1=CC=C(C=2C=CC(CC3=NNN=N3)=CC=2)C=C1 JXUQCRSZQYGYQM-UHFFFAOYSA-N 0.000 claims 1
• 201000011040 acute kidney failure Diseases 0.000 claims 1
• 229940035676 analgesics Drugs 0.000 claims 1
• 239000000730 antalgic agent Substances 0.000 claims 1
• 230000001078 anti-cholinergic effect Effects 0.000 claims 1
• 230000001387 anti-histamine Effects 0.000 claims 1
• 210000001367 artery Anatomy 0.000 claims 1
• 230000003143 atherosclerotic effect Effects 0.000 claims 1
• 201000006491 bone marrow cancer Diseases 0.000 claims 1
• 239000000168 bronchodilator agent Substances 0.000 claims 1
• 125000000068 chlorophenyl group Chemical group 0.000 claims 1
• 208000020832 chronic kidney disease Diseases 0.000 claims 1
• 229940125904 compound 1 Drugs 0.000 claims 1
• PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims 1
• 125000006627 ethoxycarbonylamino group Chemical group 0.000 claims 1
• ZVHRTJHLSYKEAK-UHFFFAOYSA-N ethyl 2-[5-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-2-oxo-3,4-dihydroquinolin-1-yl]acetate Chemical compound CCOC(=O)CN1C(=O)CCC2=C1C=CC=C2OC1=NC(=CC(CN)=C1)C(F)(F)F ZVHRTJHLSYKEAK-UHFFFAOYSA-N 0.000 claims 1
• 208000005017 glioblastoma Diseases 0.000 claims 1
• 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 claims 1
• RWOBCYNVGGKTID-GOSISDBHSA-N methyl 2-[4-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-5-methyl-1,2-oxazol-3-yl]phenyl]methoxy]phenyl]acetate Chemical compound C1=CC(CC(=O)OC)=CC=C1OCC1=CC=C(C=2C(=C(C)ON=2)NC(=O)O[C@H](C)C=2C(=CC=CC=2)Cl)C=C1 RWOBCYNVGGKTID-GOSISDBHSA-N 0.000 claims 1
• 230000000510 mucolytic effect Effects 0.000 claims 1
• HONNWTDYWUAZJF-UHFFFAOYSA-N tert-butyl 4-[2-[4-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyindol-1-yl]acetyl]piperazine-1-carboxylate Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC1=C2C=CN(C2=CC=C1)CC(=O)N1CCN(CC1)C(=O)OC(C)(C)C HONNWTDYWUAZJF-UHFFFAOYSA-N 0.000 claims 1
• 125000003944 tolyl group Chemical group 0.000 claims 1
• 210000002700 urine Anatomy 0.000 claims 1
• 239000003814 drug Substances 0.000 abstract description 44
• 208000035475 disorder Diseases 0.000 abstract description 25
• 239000005557 antagonist Substances 0.000 abstract description 23
• 229940124597 therapeutic agent Drugs 0.000 abstract description 12
• 229940044551 receptor antagonist Drugs 0.000 abstract description 7
• 239000002464 receptor antagonist Substances 0.000 abstract description 7
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 348
• XGRLSUFHELJJAB-JGSYTFBMSA-M sodium;[(2r)-2-hydroxy-3-[(z)-octadec-9-enoyl]oxypropyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)([O-])=O XGRLSUFHELJJAB-JGSYTFBMSA-M 0.000 description 346
• 239000000203 mixture Substances 0.000 description 117
• 238000009472 formulation Methods 0.000 description 89
• 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 description 45
• 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 description 45
• 235000002639 sodium chloride Nutrition 0.000 description 43
• 230000000694 effects Effects 0.000 description 41
• 125000001424 substituent group Chemical group 0.000 description 41
• 239000000460 chlorine Substances 0.000 description 38
• 210000004027 cell Anatomy 0.000 description 37
• 230000004913 activation Effects 0.000 description 32
• 210000002950 fibroblast Anatomy 0.000 description 32
• 229940079593 drug Drugs 0.000 description 29
• 102000005962 receptors Human genes 0.000 description 24
• 108020003175 receptors Proteins 0.000 description 24
• 230000001965 increasing effect Effects 0.000 description 23
• 210000004072 lung Anatomy 0.000 description 21
• 230000014509 gene expression Effects 0.000 description 20
• 230000004044 response Effects 0.000 description 20
• 239000007787 solid Substances 0.000 description 20
• 208000027418 Wounds and injury Diseases 0.000 description 18
• 125000004429 atom Chemical group 0.000 description 18
• 239000003795 chemical substances by application Substances 0.000 description 17
• 208000014674 injury Diseases 0.000 description 16
• 241000699670 Mus sp. Species 0.000 description 15
• 230000004663 cell proliferation Effects 0.000 description 15
• 239000011248 coating agent Substances 0.000 description 15
• 238000013508 migration Methods 0.000 description 15
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 14
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 14
• 230000006378 damage Effects 0.000 description 14
• 125000005551 pyridylene group Chemical group 0.000 description 14
• 210000002216 heart Anatomy 0.000 description 13
• 230000005764 inhibitory process Effects 0.000 description 13
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 13
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 13
• 230000035755 proliferation Effects 0.000 description 13
• 230000029663 wound healing Effects 0.000 description 13
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
• 238000000576 coating method Methods 0.000 description 12
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 12
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 12
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 12
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 12
• 239000000843 powder Substances 0.000 description 12
• 210000004556 brain Anatomy 0.000 description 11
• 230000012292 cell migration Effects 0.000 description 11
• 239000002245 particle Substances 0.000 description 11
• 230000011664 signaling Effects 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 10
• 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 10
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 10
• 206010061218 Inflammation Diseases 0.000 description 10
• 230000002159 abnormal effect Effects 0.000 description 10
• 230000035508 accumulation Effects 0.000 description 10
• 238000009825 accumulation Methods 0.000 description 10
• 239000004480 active ingredient Substances 0.000 description 10
• UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 10
• 125000004404 heteroalkyl group Chemical group 0.000 description 10
• 230000004054 inflammatory process Effects 0.000 description 10
• 210000003734 kidney Anatomy 0.000 description 10
• 238000004519 manufacturing process Methods 0.000 description 10
• 230000005012 migration Effects 0.000 description 10
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 238000001356 surgical procedure Methods 0.000 description 10
• 238000013268 sustained release Methods 0.000 description 10
• 239000012730 sustained-release form Substances 0.000 description 10
• 201000001320 Atherosclerosis Diseases 0.000 description 9
• 102000004127 Cytokines Human genes 0.000 description 9
• 108090000695 Cytokines Proteins 0.000 description 9
• 102000030621 adenylate cyclase Human genes 0.000 description 9
• 108060000200 adenylate cyclase Proteins 0.000 description 9
• 230000033115 angiogenesis Effects 0.000 description 9
• 208000010668 atopic eczema Diseases 0.000 description 9
• 230000008901 benefit Effects 0.000 description 9
• 238000013270 controlled release Methods 0.000 description 9
• 238000005859 coupling reaction Methods 0.000 description 9
• 238000001727 in vivo Methods 0.000 description 9
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 9
• 239000002207 metabolite Substances 0.000 description 9
• 208000010125 myocardial infarction Diseases 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 8
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 8
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
• 206010020751 Hypersensitivity Diseases 0.000 description 8
• 208000029523 Interstitial Lung disease Diseases 0.000 description 8
• 241000700159 Rattus Species 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 229920002472 Starch Polymers 0.000 description 8
• 230000009471 action Effects 0.000 description 8
• 208000026935 allergic disease Diseases 0.000 description 8
• 239000011230 binding agent Substances 0.000 description 8
• 239000011575 calcium Substances 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• 210000002744 extracellular matrix Anatomy 0.000 description 8
• 230000003176 fibrotic effect Effects 0.000 description 8
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 8
• 238000002156 mixing Methods 0.000 description 8
• 230000008506 pathogenesis Effects 0.000 description 8
• 229920000728 polyester Polymers 0.000 description 8
• 229920001223 polyethylene glycol Polymers 0.000 description 8
• 239000003755 preservative agent Substances 0.000 description 8
• 230000002206 pro-fibrotic effect Effects 0.000 description 8
• 230000008439 repair process Effects 0.000 description 8
• 210000002966 serum Anatomy 0.000 description 8
• 210000003491 skin Anatomy 0.000 description 8
• 239000003381 stabilizer Substances 0.000 description 8
• 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 description 7
• 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 description 7
• 208000006011 Stroke Diseases 0.000 description 7
• 102000014384 Type C Phospholipases Human genes 0.000 description 7
• 108010079194 Type C Phospholipases Proteins 0.000 description 7
• 125000003545 alkoxy group Chemical group 0.000 description 7
• 230000000172 allergic effect Effects 0.000 description 7
• 230000004071 biological effect Effects 0.000 description 7
• 125000004122 cyclic group Chemical group 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 230000018109 developmental process Effects 0.000 description 7
• 210000002919 epithelial cell Anatomy 0.000 description 7
• 235000019441 ethanol Nutrition 0.000 description 7
• 125000003709 fluoroalkyl group Chemical group 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 239000007788 liquid Substances 0.000 description 7
• 210000000651 myofibroblast Anatomy 0.000 description 7
• 125000004957 naphthylene group Chemical group 0.000 description 7
• 208000021722 neuropathic pain Diseases 0.000 description 7
• 229910052757 nitrogen Inorganic materials 0.000 description 7
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 7
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 7
• 229910052760 oxygen Inorganic materials 0.000 description 7
• 230000037361 pathway Effects 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 235000019698 starch Nutrition 0.000 description 7
• 229940032147 starch Drugs 0.000 description 7
• 239000008107 starch Substances 0.000 description 7
• 210000001541 thymus gland Anatomy 0.000 description 7
• LLIFMNUXGDHTRO-UHFFFAOYSA-N 3-[({4-[4-({[1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(=O)NC=1C(C)=NOC=1C1=CC=C(CSCCC(O)=O)C=C1 LLIFMNUXGDHTRO-UHFFFAOYSA-N 0.000 description 6
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
• 206010003445 Ascites Diseases 0.000 description 6
• KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 6
• 102000030782 GTP binding Human genes 0.000 description 6
• 108091000058 GTP-Binding Proteins 0.000 description 6
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
• 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 239000002585 base Substances 0.000 description 6
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
• 150000001721 carbon Chemical group 0.000 description 6
• 235000010980 cellulose Nutrition 0.000 description 6
• 229920002678 cellulose Polymers 0.000 description 6
• 239000001913 cellulose Substances 0.000 description 6
• 230000008602 contraction Effects 0.000 description 6
• 230000008878 coupling Effects 0.000 description 6
• 238000010168 coupling process Methods 0.000 description 6
• 210000002889 endothelial cell Anatomy 0.000 description 6
• 230000002708 enhancing effect Effects 0.000 description 6
• 239000000945 filler Substances 0.000 description 6
• 239000000796 flavoring agent Substances 0.000 description 6
• 239000008101 lactose Substances 0.000 description 6
• 210000004185 liver Anatomy 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 230000002503 metabolic effect Effects 0.000 description 6
• 229910052751 metal Inorganic materials 0.000 description 6
• 239000002184 metal Substances 0.000 description 6
• 210000000496 pancreas Anatomy 0.000 description 6
• 230000002062 proliferating effect Effects 0.000 description 6
• 210000002307 prostate Anatomy 0.000 description 6
• 230000007115 recruitment Effects 0.000 description 6
• 230000028327 secretion Effects 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 230000004083 survival effect Effects 0.000 description 6
• 210000001550 testis Anatomy 0.000 description 6
• 230000002792 vascular Effects 0.000 description 6
• 239000000080 wetting agent Substances 0.000 description 6
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 5
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
• 102000008186 Collagen Human genes 0.000 description 5
• 108010035532 Collagen Proteins 0.000 description 5
• 229920002785 Croscarmellose sodium Polymers 0.000 description 5
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
• 201000004624 Dermatitis Diseases 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 102000016359 Fibronectins Human genes 0.000 description 5
• 108010067306 Fibronectins Proteins 0.000 description 5
• 108091006027 G proteins Proteins 0.000 description 5
• 108010010803 Gelatin Proteins 0.000 description 5
• 206010020772 Hypertension Diseases 0.000 description 5
• 229930195725 Mannitol Natural products 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
• 239000002202 Polyethylene glycol Substances 0.000 description 5
• 201000004681 Psoriasis Diseases 0.000 description 5
• 206010052428 Wound Diseases 0.000 description 5
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
• 239000000654 additive Substances 0.000 description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 239000001768 carboxy methyl cellulose Substances 0.000 description 5
• 229920001436 collagen Polymers 0.000 description 5
• 239000008121 dextrose Substances 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 239000012530 fluid Substances 0.000 description 5
• 125000004428 fluoroalkoxy group Chemical group 0.000 description 5
• 235000013355 food flavoring agent Nutrition 0.000 description 5
• 239000008273 gelatin Substances 0.000 description 5
• 229920000159 gelatin Polymers 0.000 description 5
• 229940014259 gelatin Drugs 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 235000011852 gelatine desserts Nutrition 0.000 description 5
• 125000005842 heteroatom Chemical group 0.000 description 5
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
• 150000002440 hydroxy compounds Chemical class 0.000 description 5
• 230000000977 initiatory effect Effects 0.000 description 5
• 239000000594 mannitol Substances 0.000 description 5
• 235000010355 mannitol Nutrition 0.000 description 5
• 229920000609 methyl cellulose Polymers 0.000 description 5
• 235000010981 methylcellulose Nutrition 0.000 description 5
• 239000001923 methylcellulose Substances 0.000 description 5
• 229960002900 methylcellulose Drugs 0.000 description 5
• 229940016286 microcrystalline cellulose Drugs 0.000 description 5
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
• 239000008108 microcrystalline cellulose Substances 0.000 description 5
• 125000002950 monocyclic group Chemical group 0.000 description 5
• 239000001301 oxygen Substances 0.000 description 5
• 150000003904 phospholipids Chemical class 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 125000006239 protecting group Chemical group 0.000 description 5
• 208000002815 pulmonary hypertension Diseases 0.000 description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 description 5
• 229940005550 sodium alginate Drugs 0.000 description 5
• 235000010413 sodium alginate Nutrition 0.000 description 5
• 239000000661 sodium alginate Substances 0.000 description 5
• 239000000600 sorbitol Substances 0.000 description 5
• 235000010356 sorbitol Nutrition 0.000 description 5
• 210000000952 spleen Anatomy 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 229910052717 sulfur Inorganic materials 0.000 description 5
• 239000000375 suspending agent Substances 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
• HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 4
• 108010085238 Actins Proteins 0.000 description 4
• 102000007469 Actins Human genes 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 241000416162 Astragalus gummifer Species 0.000 description 4
• 108010006654 Bleomycin Proteins 0.000 description 4
• 208000032544 Cicatrix Diseases 0.000 description 4
• 201000003883 Cystic fibrosis Diseases 0.000 description 4
• 206010014561 Emphysema Diseases 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• 208000004454 Hyperalgesia Diseases 0.000 description 4
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
• 208000002260 Keloid Diseases 0.000 description 4
• 208000019693 Lung disease Diseases 0.000 description 4
• 108091054455 MAP kinase family Proteins 0.000 description 4
• 102000043136 MAP kinase family Human genes 0.000 description 4
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical class COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
• 229920000881 Modified starch Polymers 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• 108010003541 Platelet Activating Factor Proteins 0.000 description 4
• 206010035664 Pneumonia Diseases 0.000 description 4
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
• 229920001615 Tragacanth Polymers 0.000 description 4
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
• 206010047115 Vasculitis Diseases 0.000 description 4
• 206010047139 Vasoconstriction Diseases 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 239000000443 aerosol Substances 0.000 description 4
• 239000000556 agonist Substances 0.000 description 4
• 235000010443 alginic acid Nutrition 0.000 description 4
• 229920000615 alginic acid Polymers 0.000 description 4
• 239000003963 antioxidant agent Substances 0.000 description 4
• 235000006708 antioxidants Nutrition 0.000 description 4
• 239000007900 aqueous suspension Substances 0.000 description 4
• 229960001561 bleomycin Drugs 0.000 description 4
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 4
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 208000023819 chronic asthma Diseases 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 230000007882 cirrhosis Effects 0.000 description 4
• 235000015165 citric acid Nutrition 0.000 description 4
• 238000007906 compression Methods 0.000 description 4
• 229920001577 copolymer Polymers 0.000 description 4
• 239000013078 crystal Substances 0.000 description 4
• 125000004979 cyclopentylene group Chemical group 0.000 description 4
• 230000003111 delayed effect Effects 0.000 description 4
• 230000004069 differentiation Effects 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 4
• 239000007884 disintegrant Substances 0.000 description 4
• 239000002270 dispersing agent Substances 0.000 description 4
• 239000008298 dragée Substances 0.000 description 4
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
• 238000009501 film coating Methods 0.000 description 4
• 239000007888 film coating Substances 0.000 description 4
• 239000007903 gelatin capsule Substances 0.000 description 4
• 239000008187 granular material Substances 0.000 description 4
• 238000005469 granulation Methods 0.000 description 4
• 230000003179 granulation Effects 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 230000035876 healing Effects 0.000 description 4
• 208000006454 hepatitis Diseases 0.000 description 4
• 230000009610 hypersensitivity Effects 0.000 description 4
• 238000000338 in vitro Methods 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 229940090044 injection Drugs 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 210000001117 keloid Anatomy 0.000 description 4
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
• 238000002386 leaching Methods 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• 239000000314 lubricant Substances 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 210000001616 monocyte Anatomy 0.000 description 4
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
• 210000001672 ovary Anatomy 0.000 description 4
• 229910052698 phosphorus Inorganic materials 0.000 description 4
• 230000001766 physiological effect Effects 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 125000004076 pyridyl group Chemical group 0.000 description 4
• 150000003254 radicals Chemical class 0.000 description 4
• 238000006722 reduction reaction Methods 0.000 description 4
• 238000007634 remodeling Methods 0.000 description 4
• 230000037387 scars Effects 0.000 description 4
• 210000002027 skeletal muscle Anatomy 0.000 description 4
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
• 241000894007 species Species 0.000 description 4
• DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 4
• 210000002784 stomach Anatomy 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• 239000011593 sulfur Substances 0.000 description 4
• 230000000699 topical effect Effects 0.000 description 4
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 4
• 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 4
• 210000003932 urinary bladder Anatomy 0.000 description 4
• 230000025033 vasoconstriction Effects 0.000 description 4
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
• 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 3
• 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 3
• XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 3
• 206010002329 Aneurysm Diseases 0.000 description 3
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 3
• 206010006458 Bronchitis chronic Diseases 0.000 description 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
• 229920002261 Corn starch Polymers 0.000 description 3
• 208000028006 Corneal injury Diseases 0.000 description 3
• 206010018364 Glomerulonephritis Diseases 0.000 description 3
• 241000711549 Hepacivirus C Species 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
• 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 3
• 102000016994 Lysolipids receptors Human genes 0.000 description 3
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 150000001204 N-oxides Chemical class 0.000 description 3
• 208000012902 Nervous system disease Diseases 0.000 description 3
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 108091008611 Protein Kinase B Proteins 0.000 description 3
• 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• 235000021355 Stearic acid Nutrition 0.000 description 3
• 208000007536 Thrombosis Diseases 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
• SPTSIOTYTJZTOG-UHFFFAOYSA-N acetic acid;octadecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O SPTSIOTYTJZTOG-UHFFFAOYSA-N 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• 230000010085 airway hyperresponsiveness Effects 0.000 description 3
• 239000000783 alginic acid Substances 0.000 description 3
• 229960001126 alginic acid Drugs 0.000 description 3
• 150000004781 alginic acids Chemical class 0.000 description 3
• 201000010105 allergic rhinitis Diseases 0.000 description 3
• 230000007815 allergy Effects 0.000 description 3
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 3
• 239000002870 angiogenesis inducing agent Substances 0.000 description 3
• 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 3
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
• 230000003305 autocrine Effects 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• 230000027455 binding Effects 0.000 description 3
• 230000036772 blood pressure Effects 0.000 description 3
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
• 239000004327 boric acid Substances 0.000 description 3
• 235000010338 boric acid Nutrition 0.000 description 3
• 206010006451 bronchitis Diseases 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000021164 cell adhesion Effects 0.000 description 3
• 230000003915 cell function Effects 0.000 description 3
• 230000036755 cellular response Effects 0.000 description 3
• 210000003169 central nervous system Anatomy 0.000 description 3
• 230000035605 chemotaxis Effects 0.000 description 3
• 208000007451 chronic bronchitis Diseases 0.000 description 3
• 230000006835 compression Effects 0.000 description 3
• 239000008120 corn starch Substances 0.000 description 3
• 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 3
• 125000005724 cycloalkenylene group Chemical group 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 230000007783 downstream signaling Effects 0.000 description 3
• 230000002500 effect on skin Effects 0.000 description 3
• 239000012636 effector Substances 0.000 description 3
• 230000007613 environmental effect Effects 0.000 description 3
• 125000001153 fluoro group Chemical group F* 0.000 description 3
• 125000002541 furyl group Chemical group 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 229960005150 glycerol Drugs 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 125000001188 haloalkyl group Chemical group 0.000 description 3
• 229960001340 histamine Drugs 0.000 description 3
• 210000003630 histaminocyte Anatomy 0.000 description 3
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
• 229940071826 hydroxyethyl cellulose Drugs 0.000 description 3
• 230000001969 hypertrophic effect Effects 0.000 description 3
• 230000000642 iatrogenic effect Effects 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 208000026278 immune system disease Diseases 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 230000002458 infectious effect Effects 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 210000000936 intestine Anatomy 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 230000009545 invasion Effects 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 206010025135 lupus erythematosus Diseases 0.000 description 3
• 239000011777 magnesium Substances 0.000 description 3
• 229910052749 magnesium Inorganic materials 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
• 239000003607 modifier Substances 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 208000031225 myocardial ischemia Diseases 0.000 description 3
• 125000001624 naphthyl group Chemical group 0.000 description 3
• 230000004766 neurogenesis Effects 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 125000005565 oxadiazolylene group Chemical group 0.000 description 3
• 125000005564 oxazolylene group Chemical group 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 210000001428 peripheral nervous system Anatomy 0.000 description 3
• 229940124531 pharmaceutical excipient Drugs 0.000 description 3
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
• 229940068968 polysorbate 80 Drugs 0.000 description 3
• 229920000053 polysorbate 80 Polymers 0.000 description 3
• 229940069328 povidone Drugs 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 235000018102 proteins Nutrition 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 230000002685 pulmonary effect Effects 0.000 description 3
• 235000021251 pulses Nutrition 0.000 description 3
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
• 125000000168 pyrrolyl group Chemical group 0.000 description 3
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 3
• 230000005855 radiation Effects 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 208000037803 restenosis Diseases 0.000 description 3
• 239000011435 rock Substances 0.000 description 3
• 201000000306 sarcoidosis Diseases 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 210000000813 small intestine Anatomy 0.000 description 3
• 230000016160 smooth muscle contraction Effects 0.000 description 3
• 229920003109 sodium starch glycolate Polymers 0.000 description 3
• 239000008109 sodium starch glycolate Substances 0.000 description 3
• 229940079832 sodium starch glycolate Drugs 0.000 description 3
• 239000006104 solid solution Substances 0.000 description 3
• 208000020431 spinal cord injury Diseases 0.000 description 3
• 210000000273 spinal nerve root Anatomy 0.000 description 3
• 239000008117 stearic acid Substances 0.000 description 3
• 230000035882 stress Effects 0.000 description 3
• 210000003518 stress fiber Anatomy 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 208000011580 syndromic disease Diseases 0.000 description 3
• 239000007916 tablet composition Substances 0.000 description 3
• 125000000335 thiazolyl group Chemical group 0.000 description 3
• 125000005557 thiazolylene group Chemical group 0.000 description 3
• 125000001544 thienyl group Chemical group 0.000 description 3
• 238000002054 transplantation Methods 0.000 description 3
• 125000005559 triazolylene group Chemical group 0.000 description 3
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
• 239000000811 xylitol Substances 0.000 description 3
• 235000010447 xylitol Nutrition 0.000 description 3
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
• 229960002675 xylitol Drugs 0.000 description 3
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
• RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 2
• HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 206010001881 Alveolar proteinosis Diseases 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
• 206010048962 Brain oedema Diseases 0.000 description 2
• 206010006448 Bronchiolitis Diseases 0.000 description 2
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
• 239000004155 Chlorine dioxide Substances 0.000 description 2
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
• 238000006969 Curtius rearrangement reaction Methods 0.000 description 2
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
• 229920000858 Cyclodextrin Polymers 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• 208000016192 Demyelinating disease Diseases 0.000 description 2
• 206010012305 Demyelination Diseases 0.000 description 2
• 206010012438 Dermatitis atopic Diseases 0.000 description 2
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
• 206010013774 Dry eye Diseases 0.000 description 2
• 208000001708 Dupuytren contracture Diseases 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 206010063560 Excessive granulation tissue Diseases 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 206010018691 Granuloma Diseases 0.000 description 2
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
• 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 2
• 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 2
• 229920000084 Gum arabic Polymers 0.000 description 2
• 208000018565 Hemochromatosis Diseases 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 208000005615 Interstitial Cystitis Diseases 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 2
• 206010067125 Liver injury Diseases 0.000 description 2
• 206010049459 Lymphangioleiomyomatosis Diseases 0.000 description 2
• 108010027749 Lysophospholipid Receptors Proteins 0.000 description 2
• 229920002774 Maltodextrin Polymers 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 208000019695 Migraine disease Diseases 0.000 description 2
• 102000006386 Myelin Proteins Human genes 0.000 description 2
• 108010083674 Myelin Proteins Proteins 0.000 description 2
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
• 108010057466 NF-kappa B Proteins 0.000 description 2
• 102000003945 NF-kappa B Human genes 0.000 description 2
• 208000009905 Neurofibromatoses Diseases 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 102000038030 PI3Ks Human genes 0.000 description 2
• 108091007960 PI3Ks Proteins 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• 208000018737 Parkinson disease Diseases 0.000 description 2
• 208000031481 Pathologic Constriction Diseases 0.000 description 2
• 208000004362 Penile Induration Diseases 0.000 description 2
• 208000020758 Peyronie disease Diseases 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• 102000001253 Protein Kinase Human genes 0.000 description 2
• 108090000315 Protein Kinase C Proteins 0.000 description 2
• 102000003923 Protein Kinase C Human genes 0.000 description 2
• 102100037314 Protein kinase C gamma type Human genes 0.000 description 2
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 2
• 206010063837 Reperfusion injury Diseases 0.000 description 2
• 206010039085 Rhinitis allergic Diseases 0.000 description 2
• 241001303601 Rosacea Species 0.000 description 2
• 108060006706 SRC Proteins 0.000 description 2
• 108700025832 Serum Response Element Proteins 0.000 description 2
• 201000010001 Silicosis Diseases 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
• 238000006069 Suzuki reaction reaction Methods 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
• 208000024770 Thyroid neoplasm Diseases 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
• 208000024780 Urticaria Diseases 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 125000002252 acyl group Chemical group 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 238000013019 agitation Methods 0.000 description 2
• 210000001552 airway epithelial cell Anatomy 0.000 description 2
• 208000037883 airway inflammation Diseases 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 125000005360 alkyl sulfoxide group Chemical group 0.000 description 2
• 125000004414 alkyl thio group Chemical group 0.000 description 2
• 125000005218 alkyleneheteroaryl group Chemical group 0.000 description 2
• 208000002205 allergic conjunctivitis Diseases 0.000 description 2
• 229910052782 aluminium Inorganic materials 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 150000001413 amino acids Chemical group 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
• 229940125715 antihistaminic agent Drugs 0.000 description 2
• 239000003434 antitussive agent Substances 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 125000005362 aryl sulfone group Chemical group 0.000 description 2
• 125000005361 aryl sulfoxide group Chemical group 0.000 description 2
• 125000005110 aryl thio group Chemical group 0.000 description 2
• 125000004104 aryloxy group Chemical group 0.000 description 2
• 239000010425 asbestos Substances 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 208000024998 atopic conjunctivitis Diseases 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 125000002393 azetidinyl group Chemical group 0.000 description 2
• 125000004069 aziridinyl group Chemical group 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 239000000440 bentonite Substances 0.000 description 2
• 235000012216 bentonite Nutrition 0.000 description 2
• 229910000278 bentonite Inorganic materials 0.000 description 2
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
• 229960000686 benzalkonium chloride Drugs 0.000 description 2
• 125000005605 benzo group Chemical group 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
• 210000000013 bile duct Anatomy 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 230000031018 biological processes and functions Effects 0.000 description 2
• 230000008512 biological response Effects 0.000 description 2
• 239000000090 biomarker Substances 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 208000006752 brain edema Diseases 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
• 229960005069 calcium Drugs 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
• 239000000920 calcium hydroxide Substances 0.000 description 2
• 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
• 235000011116 calcium hydroxide Nutrition 0.000 description 2
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
• 230000036952 cancer formation Effects 0.000 description 2
• 231100000504 carcinogenesis Toxicity 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 230000009787 cardiac fibrosis Effects 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 230000020411 cell activation Effects 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 208000015114 central nervous system disease Diseases 0.000 description 2
• 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
• NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 2
• 235000017168 chlorine Nutrition 0.000 description 2
• 235000019398 chlorine dioxide Nutrition 0.000 description 2
• 239000000812 cholinergic antagonist Substances 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 230000006020 chronic inflammation Effects 0.000 description 2
• 208000010877 cognitive disease Diseases 0.000 description 2
• 230000037319 collagen production Effects 0.000 description 2
• 239000007891 compressed tablet Substances 0.000 description 2
• 239000003636 conditioned culture medium Substances 0.000 description 2
• 239000000562 conjugate Substances 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 210000004087 cornea Anatomy 0.000 description 2
• 229960005168 croscarmellose Drugs 0.000 description 2
• 229960000913 crospovidone Drugs 0.000 description 2
• 238000006880 cross-coupling reaction Methods 0.000 description 2
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• 125000005725 cyclohexenylene group Chemical group 0.000 description 2
• 125000004956 cyclohexylene group Chemical group 0.000 description 2
• 229940124581 decongestants Drugs 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 210000004443 dendritic cell Anatomy 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
• 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
• 238000007907 direct compression Methods 0.000 description 2
• 238000004090 dissolution Methods 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 239000007938 effervescent tablet Substances 0.000 description 2
• 238000005538 encapsulation Methods 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 210000003979 eosinophil Anatomy 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 229940066493 expectorants Drugs 0.000 description 2
• 239000000835 fiber Substances 0.000 description 2
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 2
• 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 2
• 230000037406 food intake Effects 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 229940075507 glyceryl monostearate Drugs 0.000 description 2
• 210000001126 granulation tissue Anatomy 0.000 description 2
• 150000004820 halides Chemical class 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 208000019622 heart disease Diseases 0.000 description 2
• 231100000753 hepatic injury Toxicity 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 210000003494 hepatocyte Anatomy 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 125000002883 imidazolyl group Chemical group 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 230000004068 intracellular signaling Effects 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 208000002551 irritable bowel syndrome Diseases 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 125000001786 isothiazolyl group Chemical group 0.000 description 2
• 125000000842 isoxazolyl group Chemical group 0.000 description 2
• 210000002510 keratinocyte Anatomy 0.000 description 2
• 210000003292 kidney cell Anatomy 0.000 description 2
• 235000014655 lactic acid Nutrition 0.000 description 2
• 239000004310 lactic acid Substances 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
• 229910052753 mercury Inorganic materials 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 238000006241 metabolic reaction Methods 0.000 description 2
• 230000000813 microbial effect Effects 0.000 description 2
• 206010027599 migraine Diseases 0.000 description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
• 125000002757 morpholinyl group Chemical group 0.000 description 2
• 229940066491 mucolytics Drugs 0.000 description 2
• TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
• 210000003097 mucus Anatomy 0.000 description 2
• 210000005012 myelin Anatomy 0.000 description 2
• 210000003098 myoblast Anatomy 0.000 description 2
• 230000002107 myocardial effect Effects 0.000 description 2
• FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 210000002241 neurite Anatomy 0.000 description 2
• 201000004931 neurofibromatosis Diseases 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 230000036963 noncompetitive effect Effects 0.000 description 2
• 230000000414 obstructive effect Effects 0.000 description 2
• 239000006186 oral dosage form Substances 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• 230000002611 ovarian Effects 0.000 description 2
• 125000001715 oxadiazolyl group Chemical group 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• 239000005022 packaging material Substances 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 230000003076 paracrine Effects 0.000 description 2
• 239000004031 partial agonist Substances 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 239000008177 pharmaceutical agent Substances 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
• 235000011007 phosphoric acid Nutrition 0.000 description 2
• 239000011574 phosphorus Substances 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 125000004193 piperazinyl group Chemical group 0.000 description 2
• 125000003386 piperidinyl group Chemical group 0.000 description 2
• 210000002826 placenta Anatomy 0.000 description 2
• 239000004014 plasticizer Substances 0.000 description 2
• 230000010118 platelet activation Effects 0.000 description 2
• 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 2
• 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
• 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
• 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 229920001592 potato starch Polymers 0.000 description 2
• 230000002335 preservative effect Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 125000003373 pyrazinyl group Chemical group 0.000 description 2
• 125000005550 pyrazinylene group Chemical group 0.000 description 2
• 125000003226 pyrazolyl group Chemical group 0.000 description 2
• 125000002098 pyridazinyl group Chemical group 0.000 description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 description 2
• 125000005576 pyrimidinylene group Chemical group 0.000 description 2
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
• 238000001953 recrystallisation Methods 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000000241 respiratory effect Effects 0.000 description 2
• 230000000250 revascularization Effects 0.000 description 2
• 229910052895 riebeckite Inorganic materials 0.000 description 2
• 201000004700 rosacea Diseases 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 230000037390 scarring Effects 0.000 description 2
• 210000004116 schwann cell Anatomy 0.000 description 2
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 210000002460 smooth muscle Anatomy 0.000 description 2
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
• 235000015424 sodium Nutrition 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• 229910000029 sodium carbonate Inorganic materials 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 229940100515 sorbitan Drugs 0.000 description 2
• 229940035044 sorbitan monolaurate Drugs 0.000 description 2
• 229940035049 sorbitan monooleate Drugs 0.000 description 2
• 235000011069 sorbitan monooleate Nutrition 0.000 description 2
• 239000001593 sorbitan monooleate Substances 0.000 description 2
• JLVSPVFPBBFMBE-HXSWCURESA-N sphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP([O-])(=O)OCC[N+](C)(C)C JLVSPVFPBBFMBE-HXSWCURESA-N 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 210000003594 spinal ganglia Anatomy 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 238000001694 spray drying Methods 0.000 description 2
• 230000036262 stenosis Effects 0.000 description 2
• 208000037804 stenosis Diseases 0.000 description 2
• 230000000707 stereoselective effect Effects 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
• 125000005958 tetrahydrothienyl group Chemical group 0.000 description 2
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 125000001113 thiadiazolyl group Chemical group 0.000 description 2
• 230000008719 thickening Effects 0.000 description 2
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
• 229960004906 thiomersal Drugs 0.000 description 2
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
• 230000002992 thymic effect Effects 0.000 description 2
• 201000002510 thyroid cancer Diseases 0.000 description 2
• 230000009772 tissue formation Effects 0.000 description 2
• 208000037816 tissue injury Diseases 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 235000010487 tragacanth Nutrition 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 229940116362 tragacanth Drugs 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
• 125000004306 triazinyl group Chemical group 0.000 description 2
• 125000001425 triazolyl group Chemical group 0.000 description 2
• 208000009999 tuberous sclerosis Diseases 0.000 description 2
• 210000003556 vascular endothelial cell Anatomy 0.000 description 2
• 239000001993 wax Substances 0.000 description 2
• 238000005550 wet granulation Methods 0.000 description 2
• 229910052725 zinc Inorganic materials 0.000 description 2
• 239000011701 zinc Substances 0.000 description 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
• 125000006747 (C2-C10) heterocycloalkyl group Chemical group 0.000 description 1
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
• JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
• PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
• 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
• SFCPXHKCMRZQAC-UHFFFAOYSA-N 2,3-dihydroxypropyl benzoate Chemical compound OCC(O)COC(=O)C1=CC=CC=C1 SFCPXHKCMRZQAC-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
• HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
• WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• 125000001627 3 membered heterocyclic group Chemical group 0.000 description 1
• XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
• 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000001963 4 membered heterocyclic group Chemical group 0.000 description 1
• CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
• OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
• 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
• 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
• 108010043137 Actomyosin Proteins 0.000 description 1
• 108700016155 Acyl transferases Proteins 0.000 description 1
• 208000036065 Airway Remodeling Diseases 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 244000257727 Allium fistulosum Species 0.000 description 1
• 235000008553 Allium fistulosum Nutrition 0.000 description 1
• 208000024985 Alport syndrome Diseases 0.000 description 1
• 208000035939 Alveolitis allergic Diseases 0.000 description 1
• 229920000856 Amylose Polymers 0.000 description 1
• 208000033309 Analgesic asthma syndrome Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 208000003120 Angiofibroma Diseases 0.000 description 1
• 206010003557 Asthma exercise induced Diseases 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
• JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
• 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 102000011632 Caseins Human genes 0.000 description 1
• 108010076119 Caseins Proteins 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 102000011068 Cdc42 Human genes 0.000 description 1
• 108050001278 Cdc42 Proteins 0.000 description 1
• 102100025051 Cell division control protein 42 homolog Human genes 0.000 description 1
• PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
• 240000008886 Ceratonia siliqua Species 0.000 description 1
• 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 208000000094 Chronic Pain Diseases 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 241000193155 Clostridium botulinum Species 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 208000027932 Collagen disease Diseases 0.000 description 1
• 206010010726 Conjunctival oedema Diseases 0.000 description 1
• 206010010996 Corneal degeneration Diseases 0.000 description 1
• 206010011044 Corneal scar Diseases 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
• 102000003849 Cytochrome P450 Human genes 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• 206010012441 Dermatitis bullous Diseases 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 102000001301 EGF receptor Human genes 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 102100030013 Endoribonuclease Human genes 0.000 description 1
• 101710199605 Endoribonuclease Proteins 0.000 description 1
• 206010048554 Endothelial dysfunction Diseases 0.000 description 1
• 108020002908 Epoxide hydrolase Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241001125671 Eretmochelys imbricata Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
• 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
• 206010015943 Eye inflammation Diseases 0.000 description 1
• 208000027445 Farmer Lung Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 102000009123 Fibrin Human genes 0.000 description 1
• 108010073385 Fibrin Proteins 0.000 description 1
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 108091007911 GSKs Proteins 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 208000006334 Gingival Fibromatosis Diseases 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
• 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
• 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 229920002907 Guar gum Polymers 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 208000004196 Heart Aneurysm Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 229920001499 Heparinoid Polymers 0.000 description 1
• 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 description 1
• 101001038001 Homo sapiens Lysophosphatidic acid receptor 2 Proteins 0.000 description 1
• 101001038006 Homo sapiens Lysophosphatidic acid receptor 3 Proteins 0.000 description 1
• 101001038043 Homo sapiens Lysophosphatidic acid receptor 4 Proteins 0.000 description 1
• 101001038037 Homo sapiens Lysophosphatidic acid receptor 5 Proteins 0.000 description 1
• 101000864393 Homo sapiens Protein BUD31 homolog Proteins 0.000 description 1
• 101001026864 Homo sapiens Protein kinase C gamma type Proteins 0.000 description 1
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• 208000035154 Hyperesthesia Diseases 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
• 206010021263 IgA nephropathy Diseases 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 1
• 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
• 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• 206010023330 Keloid scar Diseases 0.000 description 1
• 238000005577 Kumada cross-coupling reaction Methods 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 102000007330 LDL Lipoproteins Human genes 0.000 description 1
• 108010007622 LDL Lipoproteins Proteins 0.000 description 1
• 241000218652 Larix Species 0.000 description 1
• 235000005590 Larix decidua Nutrition 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 102100025357 Lipid-phosphate phosphatase Human genes 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 208000004852 Lung Injury Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 108070000013 Lysolipids receptors Proteins 0.000 description 1
• 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 description 1
• 102100040387 Lysophosphatidic acid receptor 2 Human genes 0.000 description 1
• 102100040388 Lysophosphatidic acid receptor 3 Human genes 0.000 description 1
• 102100040405 Lysophosphatidic acid receptor 4 Human genes 0.000 description 1
• 102100040404 Lysophosphatidic acid receptor 5 Human genes 0.000 description 1
• 108020002496 Lysophospholipase Proteins 0.000 description 1
• 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
• 239000005913 Maltodextrin Substances 0.000 description 1
• 208000024556 Mendelian disease Diseases 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 229920000715 Mucilage Polymers 0.000 description 1
• TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 101000966781 Mus musculus Lysophosphatidic acid receptor 1 Proteins 0.000 description 1
• 102000016349 Myosin Light Chains Human genes 0.000 description 1
• 108010067385 Myosin Light Chains Proteins 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 206010028735 Nasal congestion Diseases 0.000 description 1
• 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
• 208000028389 Nerve injury Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
• 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
• 239000008118 PEG 6000 Substances 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 206010034665 Peritoneal fibrosis Diseases 0.000 description 1
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
• 102000011420 Phospholipase D Human genes 0.000 description 1
• 108090000553 Phospholipase D Proteins 0.000 description 1
• 206010035737 Pneumonia viral Diseases 0.000 description 1
• 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
• 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 102100030160 Protein BUD31 homolog Human genes 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 102100027384 Proto-oncogene tyrosine-protein kinase Src Human genes 0.000 description 1
• 206010051739 Pulmonary sepsis Diseases 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
• 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 206010038687 Respiratory distress Diseases 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 206010039094 Rhinitis perennial Diseases 0.000 description 1
• 208000036284 Rhinitis seasonal Diseases 0.000 description 1
• 102000001332 SRC Human genes 0.000 description 1
• 208000008765 Sciatica Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 206010048676 Sjogren-Larsson Syndrome Diseases 0.000 description 1
• 206010072170 Skin wound Diseases 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 240000001058 Sterculia urens Species 0.000 description 1
• 235000015125 Sterculia urens Nutrition 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 230000006043 T cell recruitment Effects 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 206010069363 Traumatic lung injury Diseases 0.000 description 1
• 206010044541 Traumatic shock Diseases 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 238000010752 Ullmann ether synthesis reaction Methods 0.000 description 1
• 238000006887 Ullmann reaction Methods 0.000 description 1
• XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 1
• 208000026723 Urinary tract disease Diseases 0.000 description 1
• 208000012931 Urologic disease Diseases 0.000 description 1
• 102000003848 Uteroglobin Human genes 0.000 description 1
• 108090000203 Uteroglobin Proteins 0.000 description 1
• 206010046914 Vaginal infection Diseases 0.000 description 1
• 201000008100 Vaginitis Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 208000013521 Visual disease Diseases 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
• 239000012346 acetyl chloride Substances 0.000 description 1
• 229920001284 acidic polysaccharide Polymers 0.000 description 1
• 150000004805 acidic polysaccharides Chemical class 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 230000009798 acute exacerbation Effects 0.000 description 1
• 231100000354 acute hepatitis Toxicity 0.000 description 1
• 206010069351 acute lung injury Diseases 0.000 description 1
• 208000005298 acute pain Diseases 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• 102000045404 acyltransferase activity proteins Human genes 0.000 description 1
• 108700014220 acyltransferase activity proteins Proteins 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 230000011759 adipose tissue development Effects 0.000 description 1
• 229940040563 agaric acid Drugs 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 210000005058 airway cell Anatomy 0.000 description 1
• 210000005057 airway smooth muscle cell Anatomy 0.000 description 1
• 125000003158 alcohol group Chemical group 0.000 description 1
• IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical class O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910001413 alkali metal ion Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
• 150000003973 alkyl amines Chemical class 0.000 description 1
• 239000013566 allergen Substances 0.000 description 1
• 206010053552 allodynia Diseases 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 238000011316 allogeneic transplantation Methods 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
• 230000008382 alveolar damage Effects 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 210000004727 amygdala Anatomy 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
• 230000006909 anti-apoptosis Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 239000002518 antifoaming agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 208000007474 aortic aneurysm Diseases 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 210000001742 aqueous humor Anatomy 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 230000006793 arrhythmia Effects 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 208000024744 aspirin-induced respiratory disease Diseases 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 230000005549 barrier dysfunction Effects 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 229940116224 behenate Drugs 0.000 description 1
• UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000007893 bite-disintegration tablet Substances 0.000 description 1
• 208000029162 bladder disease Diseases 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 229910021538 borax Inorganic materials 0.000 description 1
• 150000001642 boronic acid derivatives Chemical class 0.000 description 1
• 230000004641 brain development Effects 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 210000000621 bronchi Anatomy 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 230000001593 cAMP accumulation Effects 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
• 229940095618 calcium glycerophosphate Drugs 0.000 description 1
• 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
• MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
• 239000001527 calcium lactate Substances 0.000 description 1
• 229960002401 calcium lactate Drugs 0.000 description 1
• 235000011086 calcium lactate Nutrition 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 235000011132 calcium sulphate Nutrition 0.000 description 1
• 229910000394 calcium triphosphate Inorganic materials 0.000 description 1
• 230000009400 cancer invasion Effects 0.000 description 1
• 239000007894 caplet Substances 0.000 description 1
• 239000007963 capsule composition Substances 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 210000001054 cardiac fibroblast Anatomy 0.000 description 1
• 235000010418 carrageenan Nutrition 0.000 description 1
• 229920001525 carrageenan Polymers 0.000 description 1
• 239000000679 carrageenan Substances 0.000 description 1
• 229940113118 carrageenan Drugs 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 1
• 230000034196 cell chemotaxis Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 208000029771 childhood onset asthma Diseases 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 238000011278 co-treatment Methods 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 230000000112 colonic effect Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 238000010924 continuous production Methods 0.000 description 1
• 230000037020 contractile activity Effects 0.000 description 1
• 210000003239 corneal fibroblast Anatomy 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• 239000007819 coupling partner Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229960001681 croscarmellose sodium Drugs 0.000 description 1
• 229920006037 cross link polymer Polymers 0.000 description 1
• 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 201000003146 cystitis Diseases 0.000 description 1
• 230000003436 cytoskeletal effect Effects 0.000 description 1
• 210000004292 cytoskeleton Anatomy 0.000 description 1
• GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000032459 dedifferentiation Effects 0.000 description 1
• 208000018180 degenerative disc disease Diseases 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 238000000586 desensitisation Methods 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 229960002086 dextran Drugs 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 229940096516 dextrates Drugs 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
• 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
• 235000019700 dicalcium phosphate Nutrition 0.000 description 1
• 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
• FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 125000000532 dioxanyl group Chemical group 0.000 description 1
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
• 235000019797 dipotassium phosphate Nutrition 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 125000005883 dithianyl group Chemical group 0.000 description 1
• 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
• 101150042537 dld1 gene Proteins 0.000 description 1
• WIDJMAWMNDPYFU-UHFFFAOYSA-N dodecane;magnesium Chemical compound CCCCCCCCCCCC[Mg] WIDJMAWMNDPYFU-UHFFFAOYSA-N 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 230000036267 drug metabolism Effects 0.000 description 1
• 238000007580 dry-mixing Methods 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 210000000613 ear canal Anatomy 0.000 description 1
• 229940047652 ear drops Drugs 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 239000007911 effervescent powder Substances 0.000 description 1
• 229920001971 elastomer Polymers 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 238000003821 enantio-separation Methods 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 239000006274 endogenous ligand Substances 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 230000008694 endothelial dysfunction Effects 0.000 description 1
• 210000000871 endothelium corneal Anatomy 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 239000003344 environmental pollutant Substances 0.000 description 1
• 239000003256 environmental substance Substances 0.000 description 1
• 230000009483 enzymatic pathway Effects 0.000 description 1
• 239000003248 enzyme activator Substances 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 229940031098 ethanolamine Drugs 0.000 description 1
• MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 238000001125 extrusion Methods 0.000 description 1
• 210000000416 exudates and transudate Anatomy 0.000 description 1
• 210000001508 eye Anatomy 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 208000022195 farmer lung disease Diseases 0.000 description 1
• 239000010685 fatty oil Substances 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 229950003499 fibrin Drugs 0.000 description 1
• 230000019305 fibroblast migration Effects 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 210000001650 focal adhesion Anatomy 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 210000005153 frontal cortex Anatomy 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 125000003838 furazanyl group Chemical group 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 210000004051 gastric juice Anatomy 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 210000001648 gingival epithelial cell Anatomy 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 210000003878 glomerular mesangial cell Anatomy 0.000 description 1
• 206010061989 glomerulosclerosis Diseases 0.000 description 1
• 239000000174 gluconic acid Chemical group 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 239000004220 glutamic acid Chemical group 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
• 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
• 239000001087 glyceryl triacetate Substances 0.000 description 1
• 235000013773 glyceryl triacetate Nutrition 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 235000010417 guar gum Nutrition 0.000 description 1
• 239000000665 guar gum Substances 0.000 description 1
• 229960002154 guar gum Drugs 0.000 description 1
• 229920000591 gum Polymers 0.000 description 1
• 235000019314 gum ghatti Nutrition 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 210000003780 hair follicle Anatomy 0.000 description 1
• 239000007887 hard shell capsule Substances 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 210000002837 heart atrium Anatomy 0.000 description 1
• 208000018578 heart valve disease Diseases 0.000 description 1
• 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
• 230000023597 hemostasis Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 239000002554 heparinoid Substances 0.000 description 1
• 229940025770 heparinoids Drugs 0.000 description 1
• 210000004024 hepatic stellate cell Anatomy 0.000 description 1
• 208000003215 hereditary nephritis Diseases 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 210000001320 hippocampus Anatomy 0.000 description 1
• 102000045903 human LPA Human genes 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 208000000122 hyperventilation Diseases 0.000 description 1
• 230000000870 hyperventilation Effects 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
• 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
• 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
• 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 210000001208 inner root sheath cell Anatomy 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 210000000876 intercostal muscle Anatomy 0.000 description 1
• 230000004073 interleukin-2 production Effects 0.000 description 1
• 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000007915 intraurethral administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 229940125425 inverse agonist Drugs 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 206010023332 keratitis Diseases 0.000 description 1
• 201000010666 keratoconjunctivitis Diseases 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 239000000832 lactitol Substances 0.000 description 1
• 235000010448 lactitol Nutrition 0.000 description 1
• VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
• 229960003451 lactitol Drugs 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 210000000867 larynx Anatomy 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 230000005976 liver dysfunction Effects 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 230000004904 long-term response Effects 0.000 description 1
• 230000004199 lung function Effects 0.000 description 1
• 231100000515 lung injury Toxicity 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 239000000391 magnesium silicate Substances 0.000 description 1
• 235000019792 magnesium silicate Nutrition 0.000 description 1
• 229910052919 magnesium silicate Inorganic materials 0.000 description 1
• 229960002366 magnesium silicate Drugs 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 229940035034 maltodextrin Drugs 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 235000012054 meals Nutrition 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 238000007909 melt granulation Methods 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000037353 metabolic pathway Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 238000003801 milling Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000002297 mitogenic effect Effects 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 235000013379 molasses Nutrition 0.000 description 1
• 150000002759 monoacylglycerols Chemical class 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
• 230000004660 morphological change Effects 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 230000003843 mucus production Effects 0.000 description 1
• 201000006938 muscular dystrophy Diseases 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 230000023105 myelination Effects 0.000 description 1
• 206010028537 myelofibrosis Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000014511 neuron projection development Effects 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 230000003040 nociceptive effect Effects 0.000 description 1
• 208000024696 nocturnal asthma Diseases 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 210000001331 nose Anatomy 0.000 description 1
• 208000007892 occupational asthma Diseases 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 229960002969 oleic acid Drugs 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 230000006712 oncogenic signaling pathway Effects 0.000 description 1
• 230000000771 oncological effect Effects 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 125000003551 oxepanyl group Chemical group 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 230000008050 pain signaling Effects 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 201000005675 papillary conjunctivitis Diseases 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000004963 pathophysiological condition Effects 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 239000003961 penetration enhancing agent Substances 0.000 description 1
• RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 1
• 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
• 239000002304 perfume Substances 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 201000002513 peritoneal mesothelioma Diseases 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• 208000001297 phlebitis Diseases 0.000 description 1
• 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
• 150000003017 phosphorus Chemical class 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 229940023488 pill Drugs 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 230000007505 plaque formation Effects 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 210000004224 pleura Anatomy 0.000 description 1
• 231100000719 pollutant Toxicity 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 150000004804 polysaccharides Chemical class 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229950008882 polysorbate Drugs 0.000 description 1
• 229940068977 polysorbate 20 Drugs 0.000 description 1
• 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
• 208000007232 portal hypertension Diseases 0.000 description 1
• 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
• WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
• 229940116317 potato starch Drugs 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 208000026526 progressive weakness Diseases 0.000 description 1
• 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 108010062154 protein kinase C gamma Proteins 0.000 description 1
• 230000001823 pruritic effect Effects 0.000 description 1
• 210000001243 pseudopodia Anatomy 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• 125000004292 pyrrolin-2-yl group Chemical group [H]C1([H])N=C(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000004363 pyrrolin-3-yl group Chemical group [H]C1=NC([H])([H])C([H])([H])C1([H])* 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 108010062302 rac1 GTP Binding Protein Proteins 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 208000032253 retinal ischemia Diseases 0.000 description 1
• 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• 230000033764 rhythmic process Effects 0.000 description 1
• 229940100486 rice starch Drugs 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 239000000565 sealant Substances 0.000 description 1
• 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
• 230000001932 seasonal effect Effects 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 239000002453 shampoo Substances 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 102000034285 signal transducing proteins Human genes 0.000 description 1
• 108091006024 signal transducing proteins Proteins 0.000 description 1
• 201000009890 sinusitis Diseases 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 102000030938 small GTPase Human genes 0.000 description 1
• 108060007624 small GTPase Proteins 0.000 description 1
• 235000010378 sodium ascorbate Nutrition 0.000 description 1
• PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
• 229960005055 sodium ascorbate Drugs 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 229940080237 sodium caseinate Drugs 0.000 description 1
• 229960002668 sodium chloride Drugs 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 235000011083 sodium citrates Nutrition 0.000 description 1
• APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 239000001540 sodium lactate Substances 0.000 description 1
• 235000011088 sodium lactate Nutrition 0.000 description 1
• 229940005581 sodium lactate Drugs 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 235000010956 sodium stearoyl-2-lactylate Nutrition 0.000 description 1
• 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• 235000010339 sodium tetraborate Nutrition 0.000 description 1
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
• 235000019345 sodium thiosulphate Nutrition 0.000 description 1
• PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
• KNYAZNABVSEZDS-UHFFFAOYSA-M sodium;2-octadecanoyloxypropanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C([O-])=O KNYAZNABVSEZDS-UHFFFAOYSA-M 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000007886 soft shell capsule Substances 0.000 description 1
• 239000007962 solid dispersion Substances 0.000 description 1
• 239000012439 solid excipient Substances 0.000 description 1
• 239000008347 soybean phospholipid Substances 0.000 description 1
• 206010062261 spinal cord neoplasm Diseases 0.000 description 1
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
• 238000005507 spraying Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000007940 sugar coated tablet Substances 0.000 description 1
• 238000009495 sugar coating Methods 0.000 description 1
• DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 238000003419 tautomerization reaction Methods 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
• 125000001583 thiepanyl group Chemical group 0.000 description 1
• 125000002053 thietanyl group Chemical group 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 125000005503 thioxanyl group Chemical group 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 238000003354 tissue distribution assay Methods 0.000 description 1
• 230000008467 tissue growth Effects 0.000 description 1
• 230000007838 tissue remodeling Effects 0.000 description 1
• 239000011732 tocopherol Substances 0.000 description 1
• 235000010384 tocopherol Nutrition 0.000 description 1
• 229930003799 tocopherol Natural products 0.000 description 1
• 229960001295 tocopherol Drugs 0.000 description 1
• 239000012443 tonicity enhancing agent Substances 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 229910052723 transition metal Inorganic materials 0.000 description 1
• 150000003624 transition metals Chemical class 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 229960002622 triacetin Drugs 0.000 description 1
• 125000005558 triazinylene group Chemical group 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 229940117013 triethanolamine oleate Drugs 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 229960004418 trolamine Drugs 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 230000004565 tumor cell growth Effects 0.000 description 1
• 230000005740 tumor formation Effects 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 230000009107 upstream regulation Effects 0.000 description 1
• 208000026533 urinary bladder disease Diseases 0.000 description 1
• 208000014001 urinary system disease Diseases 0.000 description 1
• 201000002327 urinary tract obstruction Diseases 0.000 description 1
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
• 229960000604 valproic acid Drugs 0.000 description 1
• 230000006496 vascular abnormality Effects 0.000 description 1
• 230000006459 vascular development Effects 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 208000009421 viral pneumonia Diseases 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1
• 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1
• 238000001238 wet grinding Methods 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 229940100445 wheat starch Drugs 0.000 description 1
• 230000037314 wound repair Effects 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1